



Article Lineage, Antimicrobial Resistance and Virulence of *Citrobacter* spp

Liyun Liu ^{1,*,†}, Liyun Qin ^{2,†}, Shuai Hao ^{3,†}, Ruiting Lan ^{4,†}, Baohong Xu ², Yumei Guo ², Ruiping Jiang ², Hui Sun ¹, Xiaoping Chen ¹, Xinchao LV ², Jianguo Xu ¹ and Chuan Zhao ^{2,*}

- State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; sunhui@icdc.cn (H.S.); chenxiaoping@icdc.cn (X.C.); xujianguo@icdc.cn (J.X.)
- ² Shijiazhuang Center for Disease Control and Prevention, Shijiazhuang 050011, China; qinliyun-2007@163.com (L.Q.); Wsws1120@163.com (B.X.); Guokexin2199@163.com (Y.G.); Jrpok97@163.com (R.J.); lvxinzhao1986@163.com (X.L.)
- ³ Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Engineering and Technology Research Center of Food Additives, Beijing Technology and Business University, Beijing 100048, China; haoshuai@btbu.edu.cn
- ⁴ School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia; r.lan@unsw.edu.au
- * Correspondence: liuliyun@icdc.cn (L.L.); shijiazhuangcdc@sina.com (C.Z.)
- + These authors contributed equally to this work.

Received: 4 February 2020; Accepted: 4 March 2020; Published: 6 March 2020



Abstract: *Citrobacter* spp. are opportunistic human pathogens which can cause nosocomial infections, sporadic infections and outbreaks. In order to determine the genetic diversity, *in vitro* virulence properties and antimicrobial resistance profiles of *Citrobacter* spp., 128 *Citrobacter* isolates obtained from human diarrheal patients, foods and environment were assessed by multilocus sequence typing (MLST), antimicrobial susceptibility testing and adhesion and cytotoxicity testing to HEp-2 cells. The 128 *Citrobacter* isolates were typed into 123 sequence types (STs) of which 101 were novel STs, and these STs were divided into five lineages. Lineages I and II contained *C. freundii* isolates; Lineage III contained all *C. braakii* isolates, while Lineage IV and V contained *C. youngae* isolates. Lineages II and IV contained more adhesive and cytotoxic isolates than Lineages I, III, and IV. Fifty-one of the 128 isolates were found to be multidrug-resistant (MDR, \geq 3) and mainly distributed in Lineages I, II, and III. The prevalence of quinolone resistance varied with Lineage III (*C. braakii*) having the highest proportion of resistant isolates (52.6%), followed by Lineage I (*C. freundii*) with 23.7%. Seven *qnrB* variants, including two new alleles (*qnrB93* and *qnrB94*) were found with Lineage I being the main reservoir. In summary, highly cytotoxic MDR isolates from diarrheal patients may increase the risk of severe disease.

Keywords: Citrobacter; sequence types; multidrug resistance; adhesion; cytotoxicity

1. Background

The genus *Citrobacter* contained 11 species, most of which are opportunistic human pathogens that can cause nosocomial infections [1], and a range of other infections [2–6]. In this study, we focus on three *Citrobacter* species, *C. freundii*, *C. youngae* and *C. braakii*, as potential foodborne pathogens. *C. freundii* is the most commonly isolated *Citrobacter* species causing diarrhea and other infections [7,8], while *C. youngae* and *C. braakii* are rarely reported to cause infections. Some *C. freundii* strains caused food poisoning or diarrhea in humans which were found to carry virulent factors, such as Shiga-like toxins, heat-stable toxins, or virulence islands [9,10]. *C. youngae* can cause peritonitis [11]. *C. braakii* has

been isolated from the peritonea of acute peritonitis patients, as well as from food products [12–15]. In our previous studies, *C. freundii* and *C. youngae* have been isolated from the fecal samples of diarrheal patients and different types of food samples, and are potential foodborne pathogens [10,16], while *C. braakii* has been isolated from food [10].

Antibiotic resistance of *Citrobacter* has increased, and multidrug-resistant (MDR) isolates have frequently been reported [10,17–21]. Frequent isolation of MDR *C. freundii* with resistance to β -lactams, quinolones and aminoglycosides has been reported by several international surveillance programs [18]. In our previous study, 31.7% of *C. freundii* isolates were MDR that were resistant to β -lactams, quinolones, aminoglycosides, tetracyclines, phenicols, sulfonamides or nitrofuran [10,16]. Furthermore, although not MDR, 4.9% were also resistant to aminoglycosides, β -lactams, and quinolones [10,16].

Antibiotic resistant *Citrobacter* often harbored extended-spectrum β-lactamase (ESBL) [1,19,20], and plasmid-mediated quinolone resistance (PMQR) determinants [21]. The prevalence of ESBL and PMQR *Citrobacter* isolates was reported from several international studies [1,19–21]. In our previous study, we identified four *C. freundii* isolates from clinical sources and foods that were ESBL producing and 21 isolates from clinical sources and foods that harbored PMQR genes, including *aac*(6')-*Ib-cr*, *qnrS1*, *qnrB9*, *qnrB13*, *qnrB16*, *qnrB17*, *qnrB63*, *qnrB76*, *qnrB77*, or *qnrB92* [10,16].

Fluoroquinolone resistance is associated with mutations in DNA gyrase and topoisomerase IV genes, in particular, mutations in the quinolone resistance-determining regions (QRDRs) of *gyrA* and *parC* genes [22]. It has been reported that *C. freundii* isolates with reduced susceptibility to fluoroquinolones were found to contain Thr83Ile or Asp87Asn mutation in *gyrA* [22,23]. In our previous study, we screened mutations in the QRDRs of *gyrA* and *parC* genes in fluoroquinolone resistant isolates. Four of the six fluoroquinolone resistant isolates were found to carry Thr59Ile, Gln111Arg and Ile134Val mutations of the *gyrA* gene [16]. However, it remains to be determined whether these mutations confer resistance to fluoroquinolones. No mutations in the QRDR region of the *parC* gene was found in the six fluoroquinolones resistant isolates [16].

To further understand the genetic diversity, virulence and antibiotic resistance of *Citrobacter spp*. From different sources, in this study, we isolated 128 *Citrobacter* isolates from diarrheal outpatients, food and environment in Shijiazhuang Hebei Province, China. We performed multilocus sequence typing (MLST) to determine the relationships of the isolates and screened for *bla*_{CTX-M}, *bla*_{SHV}, *bla*_{TEM} and *qnr* genes by PCR and mutations in *gyrA* and *parC* genes by PCR sequencing and assayed the adhesion and cytotoxicity to Hep-2 cells of all isolates.

2. Results

2.1. Multilocus Sequence Typing of Citrobacter Isolates

The 128 *Citrobacter* isolates were typed into 123 STs with the 67 *C. freundii* isolates dividing into 65 STs, the 45 *C. braakii* isolates into 42 STs and the 16 *C. younga*e isolates into 16 STs (Table 1 and Figure 1). Of the 123 STs, 101 were novel STs (from ST269 to ST387). No STs were predominant. Two STs (ST1 and ST100) of *C. freundii* each contained two isolates. ST1 contained one isolate from a diarrheal patient and one from food. ST100 contained one isolate from the environment and one from foods. ST297 of *C. braakii* each contained two isolates from diarrheal patients or foods. ST297 of *C. braakii* contained two isolates from the environment and one from food.

The concatenated sequence of the seven housekeeping genes for the 128 *Citrobacter* isolates, was used to construct a neighbor-joining tree (Figure 1). *Salmonella* LT2 was used as an outgroup. The 128 *Citrobacter* isolates were divided into five lineages with strong bootstrap support to the lineage divisions. Lineages I and II contained *C. freundii* isolates, while Lineages IV and V contained *C. youngae* isolates exclusively. Lineage III contained all *C. braakii* isolates. *Citrobacter* isolates from different sources were not grouped by source and were dispersed among different lineages (Table 1 and Figure 1).

Clusters and Species	Isolates	Year	Source	STs	Adhesion	LDH	NDR	ESBLs	qnr
Lineage I C. freundii	HB2016004 HB2016019	2016 2016	D F	17 284	*** +/-	12.4 ± 0.4 6.3 ± 2.2	2		qnrB9 qnrB9
e. jieunun	HB2016023	2016	F	288	*	8.9 ± 0.2	9	bla _{CTX-M-3} ,	aac(6')-Ib-cr,qnrBS
	LIR2016024	2016	F	289	*	205 ± 12	2	bla _{TEM-1}	,
	HB2016024		F		*	20.5 ± 1.3	3		~~~C1
	HB2016034			260		5.0 ± 1.4	7		qnrS1
	HB2016036	2016	D	298	+/-	0.6 ± 0.2	2		auuC1 auuD12
	HB2017002	2017	D	300	+/-	10.3 ± 1.8	1	bla _{CTX-M-9}	qnrS1,qnrB13 include the LexA binding site
	HB2017003	2017	D	301	*	8.9 ± 0.8	2		
	HB2017004	2017	D	85	*	12.3 ± 2.2	2		
	HB2017006	2017	D	303	**	27.3 ± 0.6	2		<i>qnrB76</i> include the LexA bindin site
	HB2017009	2017	D	304	*	11.9 ± 0.6	4		<i>qnrB76</i> include the LexA bindin site
	HB2017012	2017	D	306	*	7.1 ± 0.4	1		<i>qnrB76</i> include the LexA binding
	LIP2017016	2017	Л	309	*	15.0 ± 1.7	1		site
	HB2017016 HB2017017		D D	309 1	*	15.0 ± 1.7 15.9 ± 1.0	1 2		
	HB2017017 HB2017026	2017	D	313	**	15.9 ± 1.0 17.4 ± 1.1	6		aac(6')-Ib-cr
	HB2017020 HB2017031		D	313		17.4 ± 1.1 12.7 ± 0.2	2		qnrB9
	HB2017031	2017	E	318	+/- **	12.7 ± 0.2 19.1 ± 3.2	0		qnrB9 qnrB76
	HB2017036		E	320	**	19.1 ± 0.2 14.1 ± 0.8	3		цпг Б7 б
	HB2017038		F	324	*	14.1 ± 0.0 12.4 ± 8.9	4		qnrB94
	HB2017039	2017	F	324	*	12.4 ± 0.9 19.8 ± 5.7	2		qnrB17
	HB2017039		F	325	*	19.0 ± 0.7 6.7 ± 1.4	8		yni D17
	HB2017040 HB2017042	2017	F	328	-	8.9 ± 7.8	9	bla _{TEM-1}	
	HB2017042 HB2017045		F	331	*	3.9 ± 7.8 14.3 ± 1.8	7	bla _{CTX-M-9} , bla _{TEM-1}	qnrS1
	HB2017052	2017	F	337	**	15.5 ± 1.5	2	0111 IEM-1	
	HB2017053	2017	F	338	**	21.6 ± 2.5	4		qnrB9
	HB2017054		F	339	***	16.5 ± 3.6	2		qnrB76
	HB2017059		F	343	*	10.8 ± 0.0 12.8 ± 0.4	7	bla _{CTX-M-3} , bla _{CTX-M-9}	qnrB93
	HB2017060	2017	F	344	+/-	11.9 ± 1.6	7	bla _{CTX-M-9} , bla _{TEM-1}	
	HB2017061	2017	F	1	**	17.3 ± 2.4	2		
Lineage II	HB2016001	2016	D	269	**	11.0 ± 2.1	1		
C. freundii	HB2016002	2016	D	216	*	10.4 ± 0.2	3		
	HB2016003	2016	D	270	**	15.6 ± 1.1	1		
	HB2016006		Ē	272	**	9.3 ± 2.8	1		
	HB2016008	2016	F	274	***	22.7 ± 7.3	8	bla _{TEM-1}	aac(6')-Ib-cr,qnrE
	HB2016010	2016	E	276	*	8.4 ± 1.9	1	THE LEWIST	
	HB2016011		F	100	***	22.6 ± 3.0	1		
	HB2016012		F	277	**	16.9 ± 1.5	2		
	HB2016013		F	278	**	15.3 ± 3.9	3		
	HB2016017		F	282	***	21.4 ± 7.3	1		
	HB2016018	2016	F	283	+/-	9.2 ± 1.5	2		
	HB2017001		D	169	***	29.4 ± 5.8	2		
	HB2017008	2017	D	12	*	13.6 ± 0.7	5		
	HB2017011		D	163	**	15.8 ± 0.7	7	bla _{TEM-1}	aac(6')-Ib-cr
	HB2017013		D	307	**	6.8 ± 0.3	1	1 1.141 1	
	HB2017014		D	308	**	18.0 ± 13.5	1		
	HB2017018	2017	D	125	**	21.5 ± 7.3	2		
	HB2017019	2017	D	217	**	14.6 ± 1.4	1		
	HB2017020	2017	D	310	***	22.9 ± 0.9	1		
	HB2017022	2017	D	311	**	20.2 ± 1.3	2		
	HB2017023	2017	D	219	**	18.0 ± 3.4	3		
	1100017004	2017	D	150	**	21.2 ± 1.0	1		
	ПD2017024		D	312	*	8.0 ± 5.0	3		
	HB2017024 HB2017025	2017	D						
			D D	314	***	24.7 ± 2.7	4		
	HB2017025	2017			***	24.7 ± 2.7 20.2 ± 3.0	4 1		
	HB2017025 HB2017027	2017 2017	D	314					
	HB2017025 HB2017027 HB2017030	2017 2017 2017	D D	314 317	**	20.2 ± 3.0	1		

Table 1. Cont.

Clusters and Species	Isolates	Year	Source	STs	Adhesion	LDH	NDR	ESBLs	qnr
•	HB2017037	2017	Е	323	**	24.8 ± 6.8	1		
	HB2017041	2017	F	327	*	5.4 ± 1.6	1		
	HB2017043	2017	F	329	*	20.0 ± 0.6	1		
	HB2017046	2017	F	332	**	22.9 ± 7.0	2		
	HB2017047	2017	F	333	**	23.5 ± 5.0	6		
	HB2017049	2017	F	335	*	31.2 ± 10.2	2		
	HB2017051	2017	F	214	**	21.0 ± 4.4	2		
	HB2017055	2017	F	161	**	18.2 ± 3.1	6		
	HB2017056	2017	F	340	**	19.2 ± 3.4	4		
	HB2017057	2017	F	341	**	20.3 ± 3.3	4		
Lineage III	HB2016015	2016	F	280	+/-	3.4 ± 0.7	5		qnrS1
C. braakii	HB2016032	2016	Е	295	**	4.2 ± 4.1	5		
	HB2016033	2016	F	296	**	5.3 ± 3.2	2		
	HB2016035	2016	F	297	*	11.1 ± 2.2	6		aac(6')-Ib-cr,qnrB
	HB2017044	2017	F	330	**	20.4 ± 5.5	2		
	HB2017048	2017	F	334	*	20.6 ± 4.0	2		
	HB2017062	2017	F	345	*	14.8 ± 1.9	2		
	HB2017068	2017	F	351	**	12.5 ± 8.9	2		
	HB2017070	2017	D	353	*	9.5 ± 0.4	2		
	HB2017071	2017	D	354	*	22.2 ± 6.9	2		
	HB2017072	2017	D	355	**	25.2 ± 4.0	1		
	HB2017074	2017	D	356	***	14.9 ± 7.4	2		
	HB2017075	2017	D	357	**	25.2 ± 4.0	1		
	HB2017076	2017	D	358	**	28.9 ± 1.6	4		
	HB2017077	2017	D	357	**	13.6 ± 0.2	1		
	HB2017078	2017	D	359	+/-	13.0 ± 0.2 13.7 ± 5.7	1		
	HB2017079	2017	E	360	*	15.7 ± 0.7 15.5 ± 2.0	3		
	HB2017081	2017	E	362	**	15.5 ± 2.0 17.7 ± 0.8	2		
					**				
	HB2017082	2017	F	363	**	13.1 ± 1.9	1		
	HB2017083 HB2017084	2017 2017	F F	364 365	**	10.8 ± 0.6 13.9 ± 2.0	1 3		
	HB2017087	2017	F	367	*	3.5 ± 4.0	8		aac(6')-Ib-cr, qnrB2
	HB2017089	2017	F	369	+/-	11.7 ± 9.7	2		<i>ч</i> пг <i>Б</i> 2
	HB2017090	2017	F	370	+/-	4.5 ± 1.7	8		
	HB2017091	2017	F	371	-	4.7 ± 0.1	3		
	HB2017092	2017	F	372	*	11.7 ± 10.7	4		
	HB2017093	2017	F	373	+/-	6.5 ± 2.0	2		
	HB2017094	2017	F	81	+/-	9.8 ± 5.6	3		
	HB2017095	2017	F	225	**	6.2 ± 2.5	6	bla _{CTX-M-9}	qnrB2
	HB2017096	2017	F	374	**		6	bla emission	qni D2
		2017	г F	374 375	**	31.7 ± 4.8 175 ± 1.9		bla _{CTX-M-3}	
	HB2017097					17.5 ± 1.9	0		
	HB2017098		F	376	+/-	14.2 ± 6.5	1		ana((') II-
	HB2017099	2017	E	297	+/-	17.1 ± 1.1	6		aac(6')-Ib-cr
	HB2017100	2017	F	377	*	17.9 ± 2.2	2		
	HB2017101	2017	F	378	***	21.1 ± 5.1	2		
	HB2017102	2017	F	379	*	25.0 ± 4.2	3		
	HB2017103	2017	F	380	*	0.7 ± 0.4	4		
	HB2017104	2017	F	381	+/-	14.0 ± 1.7	3		
	HB2017105	2017	F	382	**	13.9 ± 2.9	9	bla _{TEM-1}	aac(6')-Ib-cr
	HB2017106	2017	F	383	**	18.6 ± 0.3	4		
	HB2017107	2017	F	384	*	18.5 ± 1.1	7		
	HB2017108	2017	F	385	**	13.2 ± 3.1	6	bla _{CTX-M-9}	aac(6')-Ib-cr, qnrB2
	HB2017109	2017	F	386	*	20.4 ± 2.4	1		
	HB2017110	2017	F	375	**	18.0 ± 3.0	0		
	HB2017111		F	387	**	18.0 ± 0.8	2		
Lineage IV	HB2016029	2016	D	292	+/-	6.5 ± 4.8	1		/ - N
C. youngae	HB2017007	2017	D	237	*	8.4 ± 2.3	8		aac(6')-Ib-cr
	HB2017021	2017	D	74	*	10.0 ± 0.5	3		
	HB2017029	2017	D	316	**	16.5 ± 2.5	2		
	HB2017067	2017	D	350	**	15.3 ± 2.7	1		
	HB2017086	2017	F	258	**	7.0 ± 5.1	2		

Clusters and Species	Isolates	Year	Source	STs	Adhesion	LDH	NDR	ESBLs	qnr
Lineage V	HB2016026	2016	D	183	**	17.2 ± 0.9	1		
C. youngae	HB2016027	2016	D	291	**	28.3 ± 0.5	1		
	HB2016028	2016	D	187	***	27.4 ± 1.2	0		
	HB2016031	2016	F	294	**	18.7 ± 2.7	2		
	HB2017063	2017	D	346	*	18.7 ± 1.5	2		
	HB2017064	2017	D	347	***	25.2 ± 1.4	0		
	HB2017065	2017	D	348	***	20.4 ± 4.9	7		
	HB2017066	2017	D	349	-	19.5 ± 3.2	0		
	HB2017069	2017	F	352	+/-	16.2 ± 14.6	2		
	HB2017085	2017	F	366	**	22.1 ± 6.5	1		

Table 1. Cont.

Adhesion index: ***, >50; **, >1 and <50; *, <1; +/-, ambivalent or no adhesion; -, no adhesion. LDH ($\% \pm$ SD): The lactate dehydrogenase released from Hep-2 cells; STs, sequence types; NDR, number of drugs resistance; D, F and E, isolates from diarrheal patients, foods and environment. ESBLs: extended-spectrum β -lactamase.




Figure 1. Phylogenetic relationships of the 128 *Citrobacter* isolates from this study. The phylogenetic tree of the 128 *Citrobacter* isolates was constructed using the concatenated sequences of the seven housekeeping genes by the neighbor-joining algorithm. *Salmonella* LT2 was used as an outgroup. Lineage divisions were marked. Bootstrap values of 50% or more from 1000 replicates were shown.

The STs of *C. freundii* in Lineages I and II from this study were compared with 85 STs of *C. freundii* from Maanshan Anhui Province in our previous study [10,16], only nine STs found in this study shared the same STs from Maanshan city. *C. freundii* from these two regions displayed high diversity. All STs of *C. freundii* from this study and our previous study were used to construct a phylogenetic tree. The tree was divided into six clusters with strong bootstrap support of the cluster divisions (Figure 2 and Supplementary Figure S1). Cluster 1 to 5 were the same as previously defined [16]. However, a group within cluster 1 of our previous study is now a separate cluster and named cluster 6. The STs of *C. freundii* in Lineage I and Lineage II from this study were equivalent to cluster 1 and cluster 2 in our previous study (Figure 2 and Supplementary Figure S1).

	Source	Year	Adhesion	LDH	qnr/ESBLs	NDR	Antibiotic resistance phenotype
ST298 HB2016036 ST288 HB2016023	D	2016 2016	*/-	0.6±0.2 8.9±0.2	via CTX-M-3 bia TEM-1, aac(6)-lb-cr.qorB9	2	(AMP)(CTX,CFX) www.ctx,cfz,cfz,cfz,cfz)(www.cfz),cfz),cfy)(stn,www.stn)(ttr,ddx)(d+L)(sul,sxt)(wwc)
72 ST227 AH2018013	D	2016		6.6±0.9	and the weat the reason of an electronic states of the	2	(ANP) (CFX, CFZ)
62 ST173 AH2014040	н	2014	- <i>j+</i> +/-	6.6±1.2 12.7±0.2	anr89	2	(CTX, CFZ) (AK)
- ST318 HB2017031 - ST199 AH2014016	D	2017 2014	•	4.0±0.5	qnr89	1	(CFX)(MMZ) (CAZ, FEP, CFX, CFZ, CRO)
68 66 ST303 HB2017006	D	2017		27.3±0.6	qnrB76 include the LexA binding site		(CFX)(STR)
ST222 AH2015007 ST304 HB2017009	D	2015 2017	:	13.4±3.6 11.9±0.6	gnrB76 include the LexA binding site	4	(CFX, CFZ) (AMP)(CTX,CFX)(TET)(CHL)
72 65 ST175 AH2014025	D	2014		10.3±0.6		3	(CTX, CAZ, FEP, CFX, CFZ, CRO)(AZM) (F)
84 ST174 AH2014012	D	2014 2014, 2016	- -, - or ***	11.1±1.3	pla craw a gnrB9	7 4.2.2	(AMP) (CTX, CAZ, FEP, CFX, CFZ, CRO)(AZM) (TET) (CHL)(SXT) (F) (MMP) (TX, CAZ, FEP, 051, 072, 080)(02M)(F) (MMP) (TX, 072, 072, 080) or (MMP)(573)
59 ST338 HB2017053	F	2014, 2016		14.9e2.7, 3.6e0.1 or 12.4e0.4 21.6±2.5	qnrB9	4,2,2	(ANP)(CTXCAZ,CFXTID)(AZM)(STR)
ST331 HB2017045	F	2017	•	14.3±1.8	bla CTX-M-9bla TEM-1, qnrS1	7	(AMP)(CTX,CFX,TIO)(NAL)(GEN,STR)(TET)(CHL)(SUL,SXT)
99 ST236 AH2016007 99 ST289 HB2016024	D	2016 2016		143±1.6 205±1.3		4	(AMP) (CTX, CFX, CFZ, CRO) (TET) (SXT) (AMP)(CTX,CFX,TIO)(NAL,CIP ,LEV)
65 ST328 HB2017042	F	2017		8.9±7.8	bla TEM-1	9	(AMP)CTX,CAL/EP,CFICTIC)(MI,MCN)(HA,CP,LEV)(SEN,STR(TET,DOX(CHL)SUL,SXT)(AME)
92 ST301 HB2017003	D	2017 2017	:	8.9±0.8 6.7±1.4		2	(AMP)(CFX) (AMP)(CTXCFXTIO)(NAL)(STR)(TET.DOX)(CHL)(SUL,SXT)(AMZ)
85 ST326 HB2017040 89 ST172 AH2014042	F	2017	. <i>j</i> +	6.7±1.4 7.2±2.0		4	(AMP) (CTXCFX, TO)(NAL)(STR)(TELDOX)(CHL)(SDL, SKT)(AM2) (AMP) (CTXCFX, CFZ) (AZM) (AK)
84 95 ST322 HB2017036	E	2017		14.1±0.8		3	(AMP)(CFX)(STR)
ST208 AH2014030 ST325 HB2017039	D	2014 2017	· /+	2.6±1.0 19.8±5.7	qnrB17 qnrB17	1	(CTXCFX, CFZ) (AMP)(CFX)
	D	2016		15.9±0.2		2	(AMP) (CTX, CAZ, CFX, CFZ, CRO)
60 ST232 AH2018001 52 ST337 HB2017052	F	2017 2017	 . _{or}	155±15 159±10 or 173±24		2	(AMP)(CFX) (AMP)(CFX)
ST1 HB2017017 HB2017061	D or F H	2017		3.1±0.4	qnrB77	2	(AMP)(CFX, CFZ)
87 ST211 AH2014047 87 ST324 HB2017038	F	2017		12.4±8.9	qnrB94	4	(CFX)(K4N)(TET,DOX)(SUL,SXT)
ST280 HB2018034	D or F	2015, 2008 2016		5.5±0.6 or 0.7± 0.4 5.0±1.4	aac(6')+b+cr,qnrB63, qnrS1	qnr877 7	(AMP(CA2)(NAL)(TET,DOX) or (CTX, CA2, CF2) (AMP)(CTXCFX,TIO)(NAL)(STR)(TET,DOX)(CHL)(SUL,SXT)
ST320 HB2016034	E	2017		19.1±3.2	qnrB76	0	
ST191_AH2014041	н	2014 2017	· /+	6.3±0.8 15.0±1.7	qnrB13	4	(AMP) (CTX,CFX, CFZ) (AZM) (AK) (CFX)
ST309 HB2017016 ST306 HB2017012	D	2017		7.1±0.4	qnrB76 include the LexA binding site	1	(CFX) (CFX)
- ST85 AH2011007 AH2016011 HB2017004	D or F	2016,2017, 2011	* or +/-	9.6±2.7, 0.2±0.2 or 12.3±2.2		6, 2, 2	(CAZ))(NAL)(STR)(TET)(CHL)(SUL), (AMP) (CFX, CFZ), (AMP)(CFX)
ST198 AH2014010	D	2014		12.0±1.8	qnrBt3	2	(AMP)(CTX, CFZ)
ST166 AH2014031 AH2014034 ST220 AH2015003	H D	2014 2015	- or -/+	5.7±0.6 or 7.0±1.4 13.6±2.4	qn/B76 qn/B16	1, 1	(CFX, CFZ, CRO) or (CTX,CFX, CFZ, CRO) (CFX, CFZ)
ST313 HB2017026	D	2015		13.b±2.4 17.4±1.1	qnristo aac(6')-ib-cr	6	(AMP)(TET)(NAL,CP)(TET,DOX)(CHL)(SUL,SXT)
ST313 HB2017026 ST300 HB2017002 ST339 HB2017054	D	2017	*/-	10.3±1.8 16.5±3.6	ble CTXM0 , and Land I3 include the LosA binding site anr B76	1	(CFX) (AMP)(CFX)
ST343 HB2017059	F	2017 2017		16.5±3.6 12.8±0.4	qnrB/6 bla CTX-M-3 bla CTX-M-9 qnrB93	2	(AMP)(CTX)FEP.CFX,TIO)(AMZ)(GEN,KAN,STR)(TET)(CHL)(SULSXT)
61 ST201 AH2014019 ST203 AH2014022	D	2014		4.1±0.3	qnrB92	2	(AMP)(CTX, CFX, CFZ, CRO)
ST203 AH2014022	D	2014 2016	+/-	4.2±0.9 6.3±2.2	an/B9	2	(CFX, CFZ)(AZM) (AMP)(CTXFEP.CFX,TIO)(MEN)(NAL.LEV)(STR)(TET.DO.X)(CHL)(SUL,SXT)(A.MZ)
TST344_HB2017060	F	2010	+/-	11.9±1.6	bla CTX-M-9,bla TEM-1	7	(AMP)(CTX/EP/CFX,TIO)(MLV((ML LEV)(3H))(ET/DOX)(CHL)(30L3XT)(HML) (AMP)(CTX/EP/CFX,TIO)(NAL)(GEN, STR)(TET/DOX)(CHL)(SUL3XT)
98 ST37 AH2008009	F	2008		20.2± 5.4		0	
ST341 HB2017057	F	2017 2017		229±7.0 203±3.3		4	(AMP)(CFX) (CFX)(TET)(CHL)(SULSXT)
ST333 HB2017047	F	2017		23.5±5.0		6	(AMP)(CFX,CTX)(GEN,STR)(TET)(CHL)(SUL,SXT)
-ST33 AH2007014 -ST116 AH2014015	D	2007 2014		5.3±.08 24.0±3.1	aac(6')-b-cr	2	(AMP)(NAL,CIP) (AMP) (CTX, CAZ, FEP, CFX, CFZ) (TET) (CHL) (SXT) (F)
ST314 HB2017027	D	2017	•••	247±27	and of the set	4	(AMP)(CFX)(NAL)(TET)
82 ST327 HB2017041 99 ST150 HB2017024	F	2017		5.4±1.6 21.2±1.0		1	(CFX) (CFX)
ST310 HB2017020	D	2017 2017		212±10 229±09		1	(CFX) (CFX)
ST308 HB2017014 ST125 HB2017018	D	2017		18.0±13.5		1	(CFX)
ST185 AH2014039 AH2016010	D Hor D	2017 2014, 2016	- or *	215±73 4.5±1.4 or 11.9±1.4		2 5 or 2	(CFX)(NAL) (AMP) (CTX, CAZ,CFX, CFZ) (AZM) (CIP, LEV) (GEN, AK) or (AMP) (CFX, CFZ)
ST214 AH2015009 HB2017051	D or F	2015, 2017	*or **	12.0±2.9 or 21.0±4.4		1 or 2	(CTX, CAZ,CFX, CFZ) or (CFX)(TET)
90 ST312 HB2017025 ST8 AH2015015	D	2017 2015	:	8.0±5.0 8.4±2.0		3	(AMP)(TET)(CHL) (AMP)(CFX)
ST282 HB2016017	F	2016		21.4±7.3		1	(NAL)
ST229 AH2016009 ST270 HB2016003	D	2016 2016		178±36 156±1.1		1	(CFX, CFZ) (CFX)
ST43 AH2008005	F	2008	_	14.9± 7.8		4	(ANP)(CAZ)(NAL)(TET,DOX)
54 ST84 AH2011006 99 ,ST54 AH2009001	F	2011 2009	••	3.5±0.4		1	(AMP)
95 S154 AF2009001 95 S1278 HB2018013	F	2009	*/-	22±12 153±39	bla TEM-1, qnrS1	3	(AMP)(CTX.TIO)(NAL.CP.LEV)(STR)(TET.DOX)(CHL)(SUL.S.XT) (AMP)(CFX) (MEM)
LST36 AH2007018	D	2007		16.7± 4.1		1	(AMP)
ST323 HB2017037 ST176 AH2014048	E	2017 2014	./*	248±68 137±03		1	(CFX) (CFX, CFZ)
ST317 HB2017030	D	2017		20.2±3.0		1	(TIO)
ST329 HB2017043	F	2017	:	20.0±0.6		1	(CFX)
ST340 HB2017056 ST177 AH2014046	F	2017 2014	- <i>f</i> +	192±34 6.8±2.2		4	(AMP)(CFX)(NAL)(TET,DOX) (AMP)(CTX, CAZ,CFX, CFZ)(AK)
-ST217 AH2015008 HB2017019	D	2015, 2017	+/- or **	14.5±5.3 or 14.6±1.4			(CFX, CFZ) or (CFX)
 ST44 AH2008008 ST215 AH2015013 	F	2008 2015	./+	0.1± 0.4 10.5±0.4	qnrB63	2	(AMP) (LEVNAL) (CFX, CFZ)
ST216 AH2015012 HB2016002	D	2015, 2016		8.8±1.1 or 10.4±0.2		1 or 3	(CTX, CFX, CFZ) or (AMP)(CTX;CAZ;CFX;TID)(AZ M)
ST42 4H2008004	F	2008		30±2.3	bia TEM-1, aac(6')-lb-cr	8	(AMP)(CTX)(NAL,CIPLEV)(KAN,STR)(TET,DOX)(CHL)(SUL,SXT)(AMZ)
ST86 AH2011008 AH2011009 ST276 HB2018010	F	2011 2016	* or **	0.1± 0.1 or 4.2± 1.3 8.4±1.9		2 or 1 1	AMP(CAZ) or (SXT) (CFX)
ST311 HB2017022	D	2017		20.2±1.3		2	(AMP)(CFX)
ST186 AH2014014 ST274 HB2016008	D	2014		13.5±0.4 22.7±7.3	qnrS1 bla TEM-1_aac(6)-lb-cr.qnrB2	4	(AMP)(CTX, CAZ, CFX, CFZ)(AZM) (TET) (AMP)(CTX,FEP,CFX,TIO)(NAL)(G EN,STR)(TET)(CHL)(SuL,SXT)(AMZ)
ST274 HB2016008	F F or E	2016 2016, 2017		22/17.3 22.6±3.0 or 19.4±2.5	bia TEM- (aac(o)-ib-cr,qnrbz	1	(CFX)
ST163 HB2017011	D	2017		15.8±0.7	ble TEM-1, eac(6')-ib-cr	7	(AMP)(CTX;CAZ;CFX)(AZM)(NAL;CIP;LEV)(STR)(TET;DOX)(CHL)(SUL;SXT)
ST272 HB2016006 ST161 HB2017055 AH2014018	E Dor F	2016 2014, 2017		9.3±2.8 6.2±1.4 or 18.2±3.1		1 6 or 3	(CFX) (AMP)(CFX)(NAL)(TET)(SXT)(AMZ) or (AMP) (CFX, CFZ) (AZM)
- ST235 AH2016004	D	2016		24.5±3.0		1	(CFX, CFZ)
ST212 AH2015005	D	2015 2016		23.6±0.7 8.4±2.7			(CFZ) (CFX, CFZ)
99 ST228 AH2016006 ST307 HB2017013	D	2016		6.8±0.3		1	(CFX)
9 ST321 HB2017035	E	2017		21.8±5.7		1	(CFX)
- ST210 AH2014043 ST283 HB2016018	H	2014 2016	- <i>j+</i> +/-	7.3±0.7 9.2±1.5		3	(CTX, CAZ, CFZ) (AZM) (AK) (AMP)(CFX)
ST12 AH2015001 HB2017008	D	2015, 2017		6.5±0.1 or 13.6±0.7		2 or 5	(CTX, CAZ, CFX, CFZ) (AK) or (AMP)(CTX,CFX)(TET)(CHL)(SXT)
98 ST169 HB2017001	F	2008 2017		11.0± 2.0 29.4±5.8		1	(SXT) (CFX)(CT)
ST277 HB2016012	F	2016		16.9±1.5		2	(AMP)(CFX)
52 ST219 AH2015006 AH2015017 HB2017023	D or H D	2015, 2017 2016	or ** 1	3.4±4.6, 22.0±3.4 or 18.0± 11.0±2.1	3.4	1, 1, 3	(CFZ), (CFZ) or (AMP)(CTXCAZCFXTIO)(AZM) (CFX)
	D						
98 99 LST269 HB2016001 98 ST319 HB2017032	D	2017		19.7±1.3		5	(AMP)(CFX)(TET)(CHL)(SUL,SXT)
96 ST319 HB2017032 96 ST335 HB2017049	F	2017		31.2±10.2		2	(AMP)(CFX)
ST319 HB2017032							

Figure 2. Phylogenetic relationships of the 123 *C. freundii* isolates from this study and two previous studies [10,16]. Lineages are marked on the node with roman numerals. Bootstrap values from 1000 replicates are shown on or near the nodes if \geq 50%. The presence of ESBL and *qnr* genes, source, year, NDR (number of drugs resistant to), adhesion, LDH and antibiotic resistance phenotype of an isolate is shown on the right. The tree was constructed using the neighbor joining method. ST, D, F, E, H, and LDH denote sequence types, isolates from diarrheal patients, foods, environment and healthy individuals, and lactate dehydrogenase, respectively. Adhesion index: ***, >50; **, >1 and <50; *, <1; +/-, ambivalent or no adhesion; -, no adhesion.

The 16 STs of *C. youngae* in Lineage IV and Lineage V from this study were compared with 32 STs of *C. youngae* from Maanshan, Anhui Province in our previous study. Fifteen STs from this study were novel STs, and there was little overlap of STs. All STs of *C. youngae* from this study and our previous study were used to construct a phylogenetic tree, the tree was divided into two clusters (cluster 1 and cluster 2) with strong bootstrap support of the cluster divisions, and 16 STs of *C. youngae* in Lineage IV and Lineage V from this study were equivalent to cluster 1 and cluster 2 in our previous study [10] (Figure 3),

			Source	Year	Adhesion	LDH	qnr/ESBLs	NDR	Antibiotic resistance phenotype
		T75 AH2009015	D	2009		15.2± 2.8		1	(AMP)
	98 S	T77 AH2009017	F	2009		2.2± 1.1		5	(NAL,CLP,LEV)(KAN,STR)(TET,DOX)(CHL)(SUL,SXT)
	- F	ST294 HB2016031	F	2016		18.7±2.7		2	(AMP) (CFX)
	97 S	T348 HB2017065	D	2017	***	20.4±4.9		7	(AMP)(CFX)(NAL)(STR)(TET,DOX)(CHL)(SUL)
		T30 AH2007009	D	2007		3.7± 1.2		5	(AMP)(CTX,CAZ) (SXT) (TET,DOX)
	- S	T27 AH2007004	D	2007		37.1±2.6		2	(AMP) (CTX,TIO)
0.020	- s	T183 HB2016026	D	2016		17.2±0.9		1	(CFX)
0.020	- s	T39 AH2007022(5)	D or F	2007, 2008	*or**	21.4± 5.8, 11.9± 0.2, 0.1± 0.5, 3.3± 0.4, 19.3± 1.3		1, 2,4,1,2	(AMP); (AMP)(CAZ); (AMP)(AZM)(CAZ,CTX,TIO)(TET,DOX); (AMP); (AMP)(CAZ,CTX)
	- s	T26 AH2007003	D	2007	••	5.9± 0.1		2	(AMP) (FEP)
	Fs	T87 AH2011010	F	2011	•	15.7± 0.1		1	(AMP)
	r s	T57 AH2009004	F	2009		5.2±0.2		1	(AMP)
100	Ls	ST187 HB2016028	D	2016	***	27.4±1.2		0	
	∏r s	ST59 AH2009007 AH2009009 AH2	009012 F	2009	**,*,+/-	19.8± 3.9, 13.5± 2.3,4.8± 0.8		2, 0, 0	(AMP)(CAZ)
	54	 ST80 AH2010002 	F	2010		0.1± 1.3		2	(AMP) (CAZ)
88		ST48 AH2008010	F	2008		29.2±2.3	qnrS1	6	(AMP)(NAL, CIP, LEV)(STR)(TET, DOX)(CHL)(SUL, SXT)
ſ	78 [8	ST38 AH2007021	D	2007		11.5± 1.3		2	(AMP)(NAL,LEV)
	96 ls	T40 AH2007023	н	2007		6.6± 0.4		1	(AMP)
V	Г ^S	ST291 HB2016027	D	2016		28.3±0.5		1	(OFX)
100		ST346 HB2017063	D	2017	·	18.7±1.5		2	(AMP)(CFX)
		ST49 AH2008011	F	2008		5.7±0.2		1	(AMP)
	~~	ST347 HB2017064	D	2017	***	25.2±1.4		0	
		ST349 HB2017066	D	2017		19.5±3.2		0	
		ST352 HB2017069	F	2017	+/-	16.2±14.6		2	(AMP)(SUL)
	.00	- ST50 AH2008012	F	2008		9.2±0.2		0	
100		ST366 HB2017085	F	2017		22.1±6.5		1	(CFX)
	100	ST41 AH2007026	н	2007	***	36.5± 2.4		3	(AMP)(CAZ)(DOX)
	78	l ST53 AH2008016	н	2008	+/-	4.4±0.7		1	(AMP)
П	100 1	ST60 AH2009008	F	2009	·	0.1± 2.4		1	(SXT)
	99	- ST71 AH2009010	F	2009	***	60.4± 2.7		5	(NAL,CLP,LEV)(KAN,STR)(TET,DOX)(CHL)(SXT)
99		ST72 AH2009011	F	2009		29.4± 3.8		6	(AMP)(NAL,CLP,LEV)(KAN,STR)(TET,DOX)(CHL)(SXT,SUL)
	»	T37 AH2007019	D	2007	•	4.2± 4.2		1	(AMP)
		56 AH2009003	F	2009	••	14± 1.6		3	(AMP)(AZM)(KAN)
		ST25 AH2007001 AH2007002	D	2007		22.4± 1.1 or 9.8± 0.7		2 or 2	(CAZ)(TET,DOX) or (AMP)(SXT)
IV	1 6	ST31 AH2007010	D	2007		0.1± 1.3		1	(AMP)
10		ST350 HB2017067	D	2017		15.3±2.7		1	(CFX)
100 99		ST258 HB2017086	F	2017		7.0±5.1		2	(AMP)(CFX)
		ST316 HB2017029	D	2017		16.5±2.5		2	(AMP)(CFX)
		ST32 AH2007013	D	2007		3.2± 0.8		1	(AMP)
		TB3 AH2011005	P	2011		6.4± 1.9		1	(CAZ)
69		ST29 AH2007008 ST34 AH2007015	D	2007 2007		22.3± 1.8		2	(AMP)(CAZ)
	-lah	ST73 AH2007015 ST73 AH2009013	D	2007		18.7± 6.4		2	(AMP)(SXT)
	64 1		D		+/-	13.2± 0.7		1	(AMP)
99		ST74 AH2009014 HB2017021	F	2009, 2017 2009	+/- or *	1.4± 0.7or 10.0±0.5		2 or 3	(AMP)(SXT) or (AMP)(TET)(SUL,SXT)
	U	ST76 AH2009016	F D		_	0.1± 0.1		1	(AMP)
9	10 II	ST292 HB2016029 ST35 AH2007016	D	2016 2007	+/-	6.5±4.8		1	(CFX)
		ST28 AH2007006 AH2007007	D	2007		1.3± 0.5		2	(AMP)(SXT)
	T	ST28 AH2007006 AH2007007 ST237 HB2017007	D		••••or ••	24.1± 0.5 or 8.1± 0.5	aac(6')-lb-cr	6 or 2	(AMP)(FEP,CTX,TIO)(TET,DOX)(NAL)(AMZ)(KAN) or (AMP)(SXT)
		S1237 HB2017007 — Salmonella LT2	U	2017		8.4±2.3	aac(6')-lb-cr	8	(AMP)(CTX,CAZ,CFX)(AZM)(NAL,CIP,LEV)(KAN,STR)(TET,DOX)(CHL)(SUL,SXT)
		COMDIDING LIZ							

Figure 3. Phylogenetic relationships of the 57 *C. youngae* isolates from this study and our previous study [10]. Lineages divisions are marked on the node with roman numerals. The number in bracket after strain name denote number of strains for ST39 which includes AH2007022, AH2007024, AH2007025, AH2008001, AH2008002). Bootstrap values (numbers on or near the nodes) from 1000 replicates are shown if \geq 50%. The presence of ESBLs and *qnr* genes, source, year, NDR (the number of drugs resistant to), adhesion, LDH and antibiotic resistance phenotype of an isolate is shown on the right. The tree was constructed using the neighbor joining method. ST, D, F, H, and LDH denote sequence types, isolates from diarrheal patients, foods and healthy individuals, and lactate dehydrogenase, respectively. Adhesion index: ***, >50; **, >1 and <50; *, <1; +/-, ambivalent or no adhesion; -, no adhesion.

The 42 STs of *C. braakii* in Lineage III from this study were compared with 8 STs of *C. braakii* from Maanshan Anhui Province in our previous study [10], and only one ST was common between the two regions. All STs of *C. braakii* from this study and our previous study were used to construct a phylogenetic tree (Figure 4), and all isolates belonged to the same cluster.

We further analyzed the 123 STs using eBURST [24,25] to identify clonal complexes. In this study we defined CCs as STs shared six of the seven alleles to identify the most closely related STs [24,25]. We also retrieved all *C. freundii* STs from other countries from the public MLST database to identify CCs that include isolates from other countries. It should be noted that there is no *C. youngae* or *C. braakii* isolates from other countries in the MLST database. There were 27, 7 and 5 CCs identified for *C. freundii*, *C. youngae* and *C. braakii* isolates, respectively (Supplementary Table S1). For the 27 *C. freundii*

CCs, 17 CCs included isolates from other countries with one CC containing isolates from five different countries, 10 CCs included isolates from two different regions of China but no isolates from other countries, and only four CCs were restricted in the same region of China. For the seven *C. youngae* CCs, only one was from two different regions of China. For the five *C. braakii* CCs only one was from two different regions of China also.

	So	ource	Year	Adhesion	LDH	anr/ESBLs	NDR	Antibiotic resistance phenotype
		F	2010	-	0.1±0.5	gnrS1	7	(AMP)(NAL,CLP,LEV)(STR)(TET,DOX)(CHL)(SUL,SXT)
	C ST385 HB2017108	F	2017	**	13.2±3.1	blaCTX-M-9, aac(6)-lb-cr, qrrB2	6	(AMP)(CTX,FEP,CFX,TIO)(AZM)(NAL)(TET,DOX)(SUL,SXT)
		D	2017	+/-	13.7±5.7		1	(NAL,CLP)
	ST365 HB2017084	F	2017	**	13.9±2.0		3	(CFX)(NAL)(TET)
	- ST81 AH2011001 HB2017094	F	2017, 2011	+/- 9.8+	5.6 or 0.7±	0.1	3	(CFX)(IMI)(AMZ) or (AMP)(NAL,LEV)
	62 ST78 AH2009018	F	2009	_	4± 0.5		5	(AMP)(CAZ)(TET,DOX)(NAL)
		D	2017		22.2±6.9		2	(AMP)(CFX)
	- ST387 HB2017111	F	2017	**	18.0±0.8		2	(AMP)(CFX)
	71 F ST345 HB2017062	F	2017		14.8±1.9		2	(AMP)(CFX)
	ST380 HB2017103	F	2017		0.7±0.4		4	(AMP)(CFX)(NAL)(TET,DOX)
	53 ST369 HB2017089	F	2017	+/-	11.7±9.7		2	(CFX)(SXT)
	61- ST378 HB2017101	F	2017	***	21.1±5.1		2	(OFX)(TET)
	r'	D	2017	***	14.9±7.4		2	(AMP)(CEX)
	ST372 HB2017092	F	2017		11.7±10.7		4	(AMP)(CFX)(NAL)(STR)
	64F ST386 HB2017109	F	2017		20.4±2.4		1	(CFX)
	60 - ST296 HB2016033	F	2016	**	5.3±3.2		2	(OFX)(NAL)
	ST383 HB2017106	F	2010		18.6±0.3		4	(OFX)(NAL)(TET,DOX) (SXT)
	1	D	2017	**	28.9±1.6		4	(AMP)(CFX)(NAL)(TET,DOX)
	ST360 HB2017079	E	2017		15.5±2.0		3	(AMP)(CFX)(NAL)
	gt r ST381 HB2017104	F	2017	+/-	14.0±1.7		3	(AMP)(CFX)(TET)
	ST384 HB2017107	F	2017		18.5±1.1		7	(AMP)(CFX)(NAL)(KAN,STR)(TET,DOX)(CHL)(SUL,SXT)
	- ST364 HB2017083	F	2017		10.8±0.6		1	(CHL)
	ST367 HB2017087	F	2017		3.5±4.0	(0) // DO	8	(AMP)(CTX,CFX,TIO)(AZM)(NAL)(STR)(TET,DOX)(CHL)(SUL,SXT)
	45 - ST379 HB2017102	F	2017		25.0±4.2	aac(6')-lb-cr, qnrB2	3	(AMP)(CFX)(NAL)
	- ST82 AH2011002	F	2011	_	0.1± 0.3		3	(AMP)(CAZ)
	u	E	2017		17.7±0.8		2	(AMP)(CFX)
	ST374 HB2017096	F	2017	**	31.7±4.8	b/a CTX-M-3	6	(AMP)(CTX,CAZ,FEP,CFX,TIO)(AZM)(STR)(TET,DOX)(SUL,SXT)
	- ST377 HB2017100	F	2017		17.9±2.2	bia GIA-WP3	2	(CFX)(STR)
	100 ST51 AH2008014	F	2008		4.4± 1.8		1	(AMP)
	100 ST55 AH2009002	F	2000	-	1.7±0.1		5	(AMP)(CAZ)(TET,DOX)(SUL)
		н	2008	+/-	11.0±4.6		2	(AMP)(SXT)
	- ST32 AH2006015	F	2000	+/-	4.5±1.7		8	(AMP)(CTX,CFX,TIO)(AZM))(NAL,CLP,LEV)(GEM,STR)(TET,DOX)(SUL,SXT)(AMZ)
		D	2017	*	9.5±0.4		2	(CFX)(NAL)
		F	2017	+/-	3.4±0.7	gnrS1	5	(OFX)(NAL)(TET)(CHL)(SUL,SXT)
	79 - ST280 HB2016015	F	2010	*	20.6±4.0	qmor	2	(OFX)(TET,DOX)
	ST357 HB2017075 HB2017077	·	2017		25.2±4.0		1	(CFX)
	a ST373 HB2017093	F	2017	+/-	6.5±2.0		2	(CFX)(TET,DOX)
	BD - ST363 HB2017093	F	2017	**	13.1±1.9		1	(STR)
	ST382 HB2017105	F	2017	**	13.9±2.9	blaTEM-1, aac(6')-lb-cr	9	(AMP)(CTX,CFX,TIO)(AZM)(NAL,CLP,LEV)(GEM,STR)(TET)(CHL)(SUL,SXT)(AMZ)
	- ST330 HB2017044	F	2017		20.4±5.5	Dia i Elvi- I, aac(0)-ib-ci	2	(AMP) (CFX)
	11	F	2017		4.7±0.1		3	(CFX)(NAL)(TET,DOX)
	ST371 HB2017091	F	2009		0.5±0.1		0	
	4	F	2017	**	6.2±2.5	bla CTX-M-9, qnrB2	6	(AMP)(CTX,CFX,RIO)(NAL)(TET,DOX)(CHL)(SUL,SXT)
	100 ST225 HB2017095	F	2017	+/-	14.2±6.5	bid of A in 5, qui be	1	(OFX)
	ST376 HB2017098	F	2017	**	12.5±8.9		2	(AMP)(CFX)
55	119	F	2017	** 17 5-	±1.9 or 18.0	+3.0	0	V
6	gy = 313/3 Hb201/09/ Hb201/110	E	2017	**	4.2±4.1		5	(AMP) (CTX,CFX)(STR)(CHL)(SUL,SXT)
1	312331102010032	E	2017, 2016	+/-17 1-		±2.2 aac(6')-lb-cr	6	
	01201 11020100001102011000	D	2017, 2010		25.2±4.0		1	(AMP) CTX,FEP,CFX,TIO)(NAL,CLP,LEV/(STR)(DOX)(SUL,SXT) or (AMP)(CTX,CFX,TIO)(NAL,CLP,LEV)(TET,DOX)(CHL)(SUL,SXT) (CFX)
_	31555 1162017072	5	2017		20.214.0			(or s)
	Salmonella LT2		0.020					

Figure 4. Phylogenetic relationships of the 53 *C. braakii* isolates (lineage III) from this study and our previous study [10]. The phylogenetic tree of the 53 *C. braakii* isolates was constructed using the concatenated sequences of the seven housekeeping genes by the neighbor-joining method. Bootstrap values of 50% or more from 1000 replicates were shown. The presence of ESBLs and *qnr* genes, source, year, NDR (number of drugs resistant to), adhesion, LDH and antibiotic resistance phenotype of an isolate is shown on the right. The tree was constructed using the neighbor joining algorithm. ST, D, F, H, and LDH indicate sequence types, isolates from diarrheal patients, foods and healthy individuals, and lactate dehydrogenase, respectively. Adhesion index: ***, >50; **, >1 and <50; *, <1; +/-, ambivalent or no adhesion; -, no adhesion.

2.2. Prevalence of Antimicrobial Resistance

Susceptibility to 22 antibiotics was tested on the 128 *Citrobacter* isolates using the broth microdilution method according to CLSI recommendations (Table 2). All isolates were sensitive to amikacin (AMI). For the 67 *C. freundii* isolates, most were resistant to one or more of the β -lactams, especially to penicillins (58.2%), cephalosporins (9.0–94.0%), monobactams (7.5%) and carbapenems (1.5–4.5%). Resistance to the three quinolones tested ranged from 7.5% to 23.9%. Resistance to other antibiotics was as follows: Aminoglycosides (0–20.9%), tetracyclines (16.4–32.8%), phenicols (25.4%), sulfonamides (22.4–25.4%) and macrolides (10.4%). For the 45 *C. braakii* isolates, resistance to different

β-lactams was as follows: Penicillins (51.1%), cephalosporins (3.0–88.9%), monobactams (11.1%) and carbapenems (0–2.2%), and resistance to quinolones (6.7–44.4%), aminoglycosides (0–22.2%), tetracyclines (31.1–42.2%), phenicols (20.0%), sulfonamides (24.4–28.9%) and macrolides (6.7%). For 16 *C. youngae* isolates, varied resistance was found to penicillins (50.0%), cephalosporins (0–68.8%), monobactams (6.3%), quinolones (6.3–12.5%), aminoglycosides (0–12.5%), tetracyclines (12.5–18.8%), phenicols (12.5%) and sulfonamides (18.8%).

Resistance to at least one antibiotic of three or more distinct classes was defined as multidrug-resistant (MDR). We found 51 MDR isolates which were distributed in five lineages, and mainly in Lineages I, II, and III which included 14/29 (48.3%), 13/38 (34.2%) and 21/45 (46.7%) MDR isolates, respectively. Ten of the 51 MDR isolates were isolated from 2016, and the remaining 41 were from 2017; By source, 13 of the 51 MDR isolates (25.5%) were isolated from diarrheal patient, four (7.8%) from the environment and 34 (66.7%) from foods (Table 1).

There were 27 MDR *C. freundii* isolates, including 9/30 (30.0%) from diarrheal patient, 17/30 (56.7%) from foods and 1/7 (14.3%) from the environment (Table 2). A total of 58 MDR *C. freundii* isolates were isolated from this study and our previous study, including 28/94 (29.8%) from diarrheal patient, 22/41 (63.7%) from foods, 7/19 (36.8%) from healthy individuals and 1/7 (14.3%) from the environment (Supplementary Table S2).

For *C. youngae*, 3 MDR isolates were isolated from this study, including 3/12 (25.0%) from diarrheal patient (Table 2) and together with 9 MDR isolates from our previous study, 5/30 (16.7%) were from diarrheal patient, 6/24 (25.0%) from foods and 1/3 (33.3%) from healthy individuals (Supplementary Table S2).

For *C. braakii*, 21 MDR isolates were isolated from this study, including 1/8 (12.5%) from diarrheal patient, 17/33 (51.5%) from foods and 3/4 (75.0%) from the environment (Table 2). Five MDR isolates were isolated from our previous study. Taken together, the MDR rate was 1/8 (12.5%) from diarrheal patient, 22/40 (55.0%) from foods and 3/4 (75.0%) from the environment (Supplementary Table S2).

2.3. Prevalence of ESBLs and Fluoroquinolone Resistance

Among the 128 *Citrobacter* isolates, 12 ESBL isolates were detected, which harbored *bla*_{CTX-M-3}, *bla*_{CTX-M-9} or *bla*_{TEM-1}, 11 of which were MDR. No isolate carried *bla*_{SHV}, *bla*_{GES}, *bla*_{PER} or *bla*_{VEB} genes.

Thirty eight (29.7%) of the 128 *Citrobacter* isolates were resistant to fluoroquinolones, including 16 *C. freundii*, 2 *C. younga*e and 20 *C. braakii* isolates, all of which were resistant to NAL (MICs \geq 32 µg/mL); 12 resistant to CIP (MICs \geq 2 µg/mL); and 10 resistant to LEV (MICs \geq 8 µg/mL). By source, 27 (71.1%) of the 38 fluoroquinolones resistant isolates were from food, two from the environment and nine from diarrheal patients. These isolates were distributed among different phylogenetic lineages, 9/38 (23.7%) in Lineage I, 7/38 (1.8%) in Lineage II, 20/38 (52.6%) in Lineage III, one each in Lineage IV and V. Thirty three (86.8%) of the 38 fluoroquinolones resistant isolates were MDR (MDR \geq 3), and 9 (23.7%) were EMBLs carrying the *bla*_{CTX-M-3}, *bla*_{CTX-M-9}, or *bla*_{TEM-1} gene (Table 3).

Twenty eight (73.7%) of the 38 NAL-resistant isolates analyzed contained mutations in the QRDR of the *gyrA* gene, with 27 having one mutation in codon 59 (Thr59Ile) and one having three mutations in codons 59, 111and 134 (Thr59Ile, Gln111Arg and Ile134Val). No mutations were found in the QRDR region of the *parC* gene (Table 3).

Of the 28 NAL-resistant isolates with *gyrA* mutations, 12 belonged to *C. freundii*, 14 to *C. braakii*, 2 to *C. youngae*. Among the 12 *C. freundii* isolates with *gyrA* mutations, six were resistant to CIP (MIC of $\geq 4 \mu g/mL$), and five were resistant to LEV (MIC of $\geq 8 \mu g/mL$); of the 14 *C. braakii* with *gyrA* mutations, three were resistant to CIP (MIC of 8 $\mu g/mL$), and three to LEV (MIC of $\geq 8 \mu g/mL$); of the two *C. youngae* isolates with *gyrA* mutations, only one was resistant to CIP and LEV (MIC of 8 $\mu g/mL$) (Table 3).

Antibiotic	C. freun	<i>dii</i> (n = 67) Resist	tance (%)	C. young	<i>ae</i> (n = 16) Resis	tance (%)	C.braakii (n = 45) Resistance (%)			
	D (n = 30)	F (n = 30)	E (n = 7)	D (n = 12)	F (n = 4)	E (n = 0)	D (n = 8)	F (n = 33)	E (n = 4)	
PENICILLINS										
Ampicillin	15 (50.0)	23 (76.7)	1 (14.3)	5 (41.7)	3 (75.0)	0 (0)	3 (37.5)	16 (48.5)	4 (100.0)	
CEPHALOSPORINS										
Cefotaxime	6 (20.0)	12 (40.0)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	7 (21.2)	2 (50.0)	
Ceftazidime	3 (10.0)	3 (10.0)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	1 (3.0)	0 (0)	
Cefepime	0 (0)	6 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.0)	0 (0)	
Cefoxitin	28 (93.3)	29 (96.7)	6 (85.7)	8 (66.7)	3 (75.0)	0 (0)	7 (87.5)	29 (87.9)	4 (100.0)	
Ceftiofur Sodium	3 (10.0)	11 (36.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (21.2)	1 (25.0)	
MONOBACTAMS										
Aztreonam	2 (6.7)	3 (10.0)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	5 (15.2)	0 (0)	
CARBAPENEMS										
Imipenem	0 (0)	1 (3.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.0)	0 (0)	
Meropenem	0 (0)	3 (10.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
OUINOLONES										
Nalidixicacid	4 (13.3)	12 (40.0)	0 (0)	2 (16.7)	0 (0)	0 (0)	3 (37.5)	15 (45.5)	2 (50.0)	
Ciprofloxacin	2 (6.7)	4 (13.3)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	3 (9.1)	0 (0)	
Levofloxacin	1 (3.3)	4 (13.3)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	3 (9.1)	0 (0)	
AMINOGLYCOSIDES										
Gentamicin	0 (0)	7 (23.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (6.1)	0 (0)	
Amikacin	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Streptomycin	2 (6.7)	11 (36.7)	1 (14.3)	2 (16.7)	0 (0)	0 (0)	0 (0)	8 (24.2)	2 (50.0)	
Kanamycin	0 (0)	3 (10.0)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	1 (3.0)	0 (0)	
TETRACYCLINES										
Tetracycline	7 (23.3)	15 (50.0)	0 (0)	3 (25.0)	0 (0)	0 (0)	1 (12.5)	17 (51.5)	1 (25.0)	
Doxycycline	2 (6.7)	9 (30.0)	0 (0)	2 (16.7)	0 (0)	0 (0)	1 (12.5)	12 (36.4)	1 (25.0)	
PHENICOLS										
Chloramphenicol	6 (20.0)	11 (36.7)	0 (0)	2 (16.7)	0 (0)	0 (0)	0 (0)	7 (21.2)	2 (50.0)	
SULFONAMIDES										
rimethoprim/Sulfamethoxazole	4 (13.3)	13 (43.3)	0 (0)	2 (16.7)	1 (25.0)	0 (0)	0 (0)	11 (33.3)	2 (50.0)	
Sulfafurazole	3 (10.0)	12 (40.0)	0 (0)	3 (25.0)	0 (0)	0 (0)	0 (0)	9 (37.3)	2 (50.0)	
MACROLIDES										
Azithromycin	1 (3.3)	6 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (9.1)	0 (0)	
MDR	9 (30.0)	17 (56.7)	1 (14.3)	3 (25.0)	0 (0)	0 (0)	1 (12.5)	17 (51.5)	3 (75.0)	

Table 2. Prevalence of resistance to different antibiotics by species and source.

D, diarrheal patients; F, foods; E, environment. MDR: With resistance to at least one antibiotic of three or more distinct classes (MDR \geq 3).

					-	-				0
Isolates	Species	Year	Source	ST	NDR	NAL	CIP	LEV	PMQR	gyrA Position
HB2016008	C. freundii	2016	F	274	8	>128	4		aac(6')-Ib-cr,qnrE	32 Thr59Ile
HB2016017	C. freundii	2016	F	282	1	>128			,	Thr59Ile
HB2017011	C. freundii	2017	D	163	7	>64	16	8	aac(6')-Ib-cr	Thr59Ile
HB2017018	C. freundii	2017	D	125	2	>128				Thr59Ile
HB2017027	C. freundii	2017	D	314	4	>64				No mutation
HB2017055	C. freundii	2017	F	161	6	>128				Thr59Ile
HB2017056	C. freundii	2017	F	340	4	>128				Thr59Ile
HB2016019	C. freundii	2016	F	284	9	>128		8	qnrB9	Thr59Ile
HB2016023	C. freundii	2016	F	288	9	>128	32	16	aac(6')-Ib-cr, qnrB9	Thr59Ile
HB2016024	C. freundii	2016	F	289	3	>128	4	8	1	Thr59Ile
HB2016034	C. freundii	2016	F	260	7	32			qnrS1	No mutation
HB2017026	C. freundii	2017	D	313	6	>128	4		aac(6')-Ib-cr	Thr59Ile
HB2017040	C. freundii	2017	F	326	8	>128				Thr591le
HB2017042	C. freundii	2017	F	328	9	>128	8	16		Thr591le
HB2017045	C. freundii	2017	F	331	7	64			qnrS1	No mutation
HB2017060	C. freundii	2017	F	344	7	>128			,	No mutation
HB2016015	C. braakii	2016	F	280	5	>128			qnrS1	Thr59Ile
HB2016033	C. braakii	2016	F	296	2	>128			1	Thr59Ile
HB2016035	C. braakii	2016	F	297	6	>128	8	8	aac(6')-Ib-cr, qnrB2	Thr59Ile
HB2017070	C. braakii	2017	D	353	2	>64			1	Thr59Ile
HB2017076	C. braakii	2017	D	358	4	>128				Thr59Ile
HB2017078	C. braakii	2017	D	359	1	>64	2			No mutation
HB2017079	C. braakii	2017	Е	360	3	>128				Thr59Ile
HB2017084	C. braakii	2017	F	365	3	>64				Thr59Ile
HB2017087	C. braakii	2017	F	367	8	>128			aac(6′)-Ib-cr, qnrB2	Thr59Ile
HB2017090	C. braakii	2017	F	370	8	>128	8	>16	,	Thr59Ile
HB2017091	C. braakii	2017	F	371	3	>128				Thr59Ile
HB2017092	C. braakii	2017	F	372	4	64				No mutation
HB2017095	C. braakii	2017	F	225	6	>128			qnrB2	No mutation
HB2017099	C. braakii	2017	Е	297	6	>128	8	8	aac(6')-Ib-cr	Thr59Ile
HB2017102	C. braakii	2017	F	379	3	32				No mutation
HB2017103	C. braakii	2017	F	380	4	>128				Thr59Ile
HB2017105	C. braakii	2017	F	382	9	>128	8	16	aac(6')-Ib-cr	No mutation
HB2017106	C. braakii	2017	F	383	4	32				No mutation
HB2017107	C. braakii	2017	F	384	7	>128				Thr59Ile
HB2017108	C. braakii	2017	F	385	6	>128			aac(6')-Ib-cr, qnrB2	Thr59Ile
HB2017007	C. youngae	2017	D	237	8	>64	8	8	aac(6')-Ib-cr	Thr59Ile
HB2017065	C. youngae	2017	D	348	7	>128				Thr59Ile, Gln111Arg, Ile134Val

Table 3. Quinolone resistant *Citrobacter* isolates and the presence of quinolone resistance genes and alterations in the *gyrA* gene.

NAL, nalidixicacid; CIP, ciprofloxacin; LEV, levofloxacin. NDR, number of drugs resistant to. PMQR, plasmid-mediated quinolone resistance (PMQR) genes.

2.4. Prevalence of qnrB Genes

Nineteen *Citrobacter* isolates, including 4 *C. braakii* and 15 *C. freundii* isolates, were found to harbor *qnrB* genes (including *qnrB2*, *qnrB9*, *qnrB17*, *qnrB76*, *qnrB13*, *qnrB93* and *qnrB94*) (Table 1). Four *C. braakii* and one *C. freundii* isolates harbored *qnrB2*, all of which were resistant to NAL, (MICs \geq 128 µg/mL), and were MDR. *QnrB9* was found in five *C. freundii* isolates with three (HB2017053, HB2016023 and HB2017031) isolated from food and MDR, and two (HB2016004 and HB2017031) isolated from diarrheal patients and none was MDR. Among the three *qnrB9*-carrying MDR isolates, two (HB2016023 and HB2017031) were resistant to NAL (MICs \geq 128 µg/mL). *QnrB17* was harbored in one *C. freundii* isolate (HB2017039) which was isolated from food and was not MDR. *qnrB76* was harbored by two *C. freundii* isolates with one from food and one from the environment. A variant of *qnrB76* (*qnrB76* contained a LexA binding site) was harbored by three *C. freundii* isolates, all of which were isolated from diarrheal patients. A variant of *qnrB13* (*qnrB13* contained a LexA binding site) was harbored by three *C. freundii* patient.

Two isolates (HB2017059 and HB2017038) were found to harbor a new *qnrB* gene, both of which were isolated from food (Table 1). Sequence analysis revealed that the new *qnrB* gene harbored by HB2017059 differed from the *qnrB13* gene (GenBank accession no. EU273756.1) by one nucleotide change (a G→A change at nt85 resulting in Asp→Asn), and this new *qnrB* allele was assigned *qnrB93* (GenBank accession no.MK047606). The new *qnrB* gene harbored by HB2017038 differed from the *qnrB11* gene (GenBank accession no. EU136183.1) by seven nucleotide change, including two non-synonymous changes, and A→G change at nt430 resulted in Thr→Ala and an A→C change at nt556 resulted in Ile→Leu, and five synonymous changes, a T→G change at nt246, A→C change at nt357, G→A change at nt399, C→T change at nt468 and G→C change at nt564. This new *qnrB* allele was assigned *qnrB94* (GenBank accession no.MK047607) [26].

qnrB genes were predominantly harboured by Lineage I (*C. freundii*) (Table 1). When all *C. freundii* data combined, 26/53 (49.1%) Lineage I isolates carried a *qnrB* allele (Figure 2).

2.5. Adherence and Cytotoxicity of Citrobacter Isolates

The 128 *Citrobacter* isolates were tested for adhesion and cytotoxicity to Hep-2 cells as done previously [10] (Table 1). Fourteen isolates (10.9%) had an adhesion index greater than 50 and were classified as high adhesion. Fifty-seven (44.5%) isolates had an adhesion index between 1 and 50 and were regarded as intermediate adhesive. Thirty seven (28.9%) isolates showed little adhesion (adhesion index of <1). The remaining 20 (15.6%) isolates showed ambivalent adhesion or no adhesion. By cytotoxicity, of the 128 isolates, 13 (10.2%) were highly cytotoxic, 40 (31.3%) intermediate cytotoxic and 75 (58.6%) non-cytotoxic.

Among the 14 highly adhesive isolates, four isolates released LDH more than 24%, and were considered highly cytotoxic (Figure 5); seven isolates released LDH from 19.4% to 22.9% and were considered intermediate cytotoxic; the remaining three isolates showed LDH release less than 16.5% and were likely to be non-cytotoxic (Table 1 and Supplementary Table S3).

Among the 57 intermediate adhesive isolates, seven isolates showed high cytotoxicity with more than 24% LDH released (Figure 5); 23 isolates released LDH from 18.0% to 23.5% and were intermediate cytotoxic, the remaining 27 isolates were considered to be non-cytotoxic (Table 1 and Supplementary Table S3).




Figure 5. Adhesion and cytotoxicity of *Citrobacter* isolates to the human epidermoid laryngocarcinoma (Hep-2, CCC0068) cell line. (**A**) Light micrographs of the adherence patterns exhibited by the 13 highly cytotoxic *Citrobacter* isolates, and control strains CF74 and CF72. Bar: 10µm. (**B**) Cytotoxicity of the 13 highly cytotoxic *Citrobacter* isolates was measured by the amount of the LDH released after 8 h exposure by Hep-2 cells. CF72 and CF74 were control strains. CF72 was a non-cytotoxic and non-adhesive negative control, CF74 was a highly adherent and cytotoxic positive control.

Among the 37 less adhesive isolates, two showed high cytotoxicity with more than 24% LDH released (Figure 5); nine were considered intermediate cytotoxic which released LDH from 17.9% to 22.2%; the remaining 26 isolates showed LDH release less than 15.9% and are likely to be non-cytotoxic (Table 1 and Supplementary Table S3).

The 20 non adhesive isolates were also non-cytotoxic with all, except one showing intermediate cytotoxicity, releasing LDH from 0.6% to 17.1% (Table 1 and Supplementary Table S3).

We examined any differences in adhesion and cytotoxicity between lineages. We analyzed the difference using data in this study alone (Figure 6A,C) and also using combined data with our two previous studies (Figure 6B,D). Between Lineages I and II which exclusively contained *C. freundii* isolates, Lineage II showed higher proportion of high or intermediate adhesive and cytotoxic isolates than in Lineage I and the difference is statistically significant (p < 0.01) (Figure 6); Between Lineage IV and V which contained only *C. youngae* isolates, the percentage of highly adhesive isolates in Lineage V was higher than in Lineage IV (p < 0.01) (Figure 6A,C), and the percentage of the highly or intermediate cytotoxic isolates in Lineage V was also higher than in Lineage IV (p < 0.05) (Figure 6B,D). When the two virulence traits were considered together, Lineages II and V had higher adhesive and cytotoxic isolates than Lineage I, III, and IV (Figure 7).




Figure 6. The percentage of adhesive and cytotoxic isolates in different lineages. (**A**) and (**B**) The percentage of high, intermediate, little or no adhesive or cytotoxic isolates based on the 128 *Citrobacter* isolates from this study. (**C**) and (**D**) The percentage of high, intermediate, little or no adhesive or cytotoxic isolates in different lineages based on the128 *Citrobacter* isolates from this study and 95 *Citrobacter* isolates from our previous studies [10,16]. The statistical significance between Lineages I and II or Lineages IV and V was determined by Mann-Whitney U test. *, p < 0.05; **, p < 0.01.




Figure 7. The number of adhesive and cytotoxic isolates in different lineages. The data were based on 128 isolates from this study and 95 *Citrobacter* isolates from our previous studies [10,16].

3. Discussion

Citrobacter spp. are opportunistic pathogens that can cause diarrhea, septicemia, meningitis, and urinary tract infections, especially in immunocompromised patients [27]. Together with our previous studies [10,16], we found 25 highly cytotoxic *Citrobacter* isolates out of 271 (9.2%), 15 were isolated from diarrheal patients (11.4% of diarrheal isolates), seven from foods (6.7% food isolates), two from healthy individuals (8.7%) and 1 from the environment (9.1%). The 22 highly cytotoxic *Citrobacter* isolates were distributed among the five lineages identified. However, Lineage II (*C. freundii*) and Lineage V (*C. youngae*) disproportionally contained more adhesive and more cytotoxic isolates than Lineages I, III, and IV and are likely to pose a higher risk to human health.

3.1. High Genetic Diversity of Citrobacter spp. Across China and Internationally.

The 128 Citrobacter isolates were divided into 123 STs, displaying high genetic diversity. We compared our STs with 268 STs from the Citrobacer MLST database and found 22 STs in this study were present in the database with isolates from other countries or regions, or from different sources. Among these 22 STs, ST1 contained isolates from diarrheal patients, healthy individuals, animals, insects and environment in our previous study [9]; ST12 contained isolates from a rectal swab (Israel in 2009) and a diarrheal patient (China in 2015) [16]; ST17 contained isolates from a skin necrosis, urine (Poland, 2012), two rectal swabs (Latvia, 2008 and 2009), and two diarrheal patients (China in 2014) [16]; ST163 and ST169 contained isolates from water (Canada in 2015); ST161 contained isolates from water (Canada in 2015) and a diarrheal patient (China in 2015) [16]; ST85, ST183, ST214, ST216, ST217, ST225, and ST237 each contained isolates from diarrheal patient in our previous studies [10,18]; ST187 and ST219 each contained isolates from healthy individuals in our previous study [16]; ST258 and ST260 each contained isolates from the Netherlands. Our analysis by clonal complexes which allowed one to examine closely related STs, found 17 C. freundii CCs containing at least 2 STs per CC contained isolates from different countries with one CC present in 5 different countries. For C. youngae and C. braakii, fewer CCs were identified, and narrower geographic distribution was found. However, there was no information from other countries for comparison for these latter two species. Thus, some Citrobacter STs and CCs are likely to be widely present in fecal, food, and other reservoirs and spread in different countries or regions. However, there are very limited reports of *Citrobacter* spp. from different sources or geographical regions. A recent study in companion animals reported nosocomial dissemination of C. freundii strains resistant to extended-spectrum cephalosporins [28]. Our studies underscore the need for further study to understand the genetic diversity, virulence and antibiotic resistance and their risks to human health.

3.2. Association of C. freundii Lineage II and C. youngae Lineage V with Higher Adhesion and Cytotoxicity

The clustering of highly adhesive and cytotoxic isolates in specific lineages is most interesting as it suggests that different lineages have different levels of virulence and/or may cause different types of diseases. Combining this study with our previous studies [10,16], there were nine highly cytotoxic *C. freundii* isolates, of which six were isolated from diarrheal patients, two from foods, and one from the environment. Among these six highly cytotoxic *C. freundii* isolates from diarrheal patients, five isolates were clustered in Lineage II and one in Lineage I, suggesting that Lineage II is more likely to cause diarrheal disease. *C. freundii*, as the most common *Citrobacter* species, has caused gastroenteritis associated outbreaks [3]. However, despite reports of different virulence factors involved [9,10], little is known of its pathogenic mechanisms and there have been no means that can differentiate strains that can cause diarrheal disease from those of harmless colonizers. The identification of Lineage II as more likely to cause diarrheal provided an avenue to further identify virulence genes involved and to determine whether Lineage II is more likely to cause other infections.

Similarly, combining with our previous studies [10,16], seven of the eight highly cytotoxic *C. youngae* strains fell into Lineage V, of which four were isolated from diarrheal patients, suggest

that Lineage V is likely to cause diarrheal disease. However, *C. younage* had not been recognized as a diarrheal pathogen and Lineage V should be further investigated for their potential to cause diarrheal disease.

C. braakii has been isolated from foods, hospital infections and UTIs [14], and acute peritonitis patients [7,8]. In our previous study, we isolated *C. braakii* isolates from food source, but not human fecal samples [10]. In this study, we obtained 45 *C. braakii* isolates from food, environment and diarrheal patients with two highly adhesive and five highly cytotoxic isolates. Three of the five highly cytotoxic *C. braakii* isolates were isolated from diarrheal patients, and it remains to be determined whether *C. braakii* can cause diarrhea.

3.3. Higher Prevalence of Multidrug Resistance in C. braakii Isolates and Citrobacter Isolates from Food Sources

MDR has been reported in *Citrobacter* isolates, especially *C. freundii* [17]. Considering isolates from this study only, 58 of the 128 isolates were MDR, mainly distributed among Lineages I to III. When combined with our previous studies [10,16], 96 of the 271 *Citrobacter* isolates (35.4%) were MDR, including 58 *C. freundii* isolates (36.0% of *C. freundii* isolates, Lineages I and II), 12 *C. youngae* isolates (21.1% of *C. youngae* isolates, Lineages IV and V) and 26 *C. braakii* isolates (49.0% of *C. braakii* isolates, Lineage III). The difference in the prevalence of MDR between *C. youngae* and *C. braakii* is statistically significant (p < 0.01).

Among the 96 MDR isolates, 34 were isolated from diarrheal patients (25.8% of diarrheal isolates), 50 from foods (47.6% of the food isolates), four from the environment (36.4%) and eight from healthy individuals (34.8%). Interestingly MDR were more prevalent among food isolates. Since most of the food source was related to meat or meat products [10,16], the MDR may have been a result of extensive use of antibiotics in animals. Moreover, four highly cytotoxic strains (11.8%) were found in 34 MDR isolates from diarrheal patients, highlighting the combined increased risk of high cytotoxicity and MDR of *Citrobacter* to human health.

3.4. Carriage of ESBL Genes by Citrobacter spp. was Relatively Low

ESBL producing *Enterobacteriaceae* has been a major challenge in infection control [29,30]. Previous studies have reported that *Citrobacter* isolated from human clinical infections that carried ESBL genes varied from 5.6% to 67.5%, including *bla*_{TEM-1}, *bla*_{SHV-12}, *bla*_{CTX-M-15} and *bla*_{CTX-M} [3,28]. In our studies, including our previous studies [10,16], we found 2.6% of *Citrobacter* isolates carried the *bla*_{CTX-M-9} gene, 1.1% carried the *bla*_{CTX-M-3} gene, 3.7% carried the *bla*_{TEM-1} gene, and none carried the *bla*_{SHV} gene. The ESBL carrying *Citrobacter* isolates consisted of 12 *C. freundii* isolates (7.5% of *C. freundii* isolates) and four *C. braakii* isolates (7.5% of *C. braakii* isolates). The four ESBL carrying *C. braakii* isolates were isolated from foods. Three of the 12 ESBLs carrying *C. freundii* isolates were isolated from healthy individuals (4.3%). In comparison to other reports, ESBL carriage is lower in our isolates. The isolates of our previous two studies [10,16] were from the south of China (Anhui province), while isolates of this study were from northern China (Hebei Province), suggesting likely low prevalence of ESBLs in *Citrobacter* spp. In China. However, other regions of China would need to be sampled to obtain a more comprehensive picture.

3.5. Higher Prevalence of Quinolone Resistance in Lineages I and III of Citrobacter spp with Multiple Mechanism of Resistance Detected

The prevalence of quinolone resistance varied among the lineages. Lineage III (*C. braakii*) had the highest proportion of resistance isolates (52.6%), followed by Lineage I (*C. freundii*) with 23.7%. We analyzed the carriage of potential quinolone resistance genes or mutations which include both the QRDR of *gyrA* and *parC* associated resistance, and PMQR genes mediated resistance [22]. *Citrobacter* isolates with mutations in the QRDR of *gyrA*, *including* Thr83Ile and Asp87Asn have shown reduced susceptibility to fluoroquinolones [22,23]. In our previous study [18], four (66.7%) of the six

ciprofloxacin-resistant *C. freundii* isolates were found to have mutations in codons 59, 111, and/or 134 in the QRDR region of the *gyrA* gene, namely, Thr59Ile, Gln111Arg, and Ile134Val. In this study, 28 ciprofloxacin-resistant isolates carried mutations in the QRDR of *gyrA* with 27 having one mutation, Thr59Ile and one having three mutations, Thr59Ile, Gln111Arg and Ile134Val. However, it should be noted that these three mutations have not been experimentally confirmed whether they affect fluoroquinolone resistance.

For PMQR gene-mediated resistance, 14.0% of our *Citrobacter* isolates carried a *qnr* gene, and 5.5% of *Citrobacter* isolates carried the *aac*(6')-*Ib-cr* gene. Our results contrast previous reports of high prevalence of *qnr* and *aac*(6')-*Ib-cr* genes from clinical infections in China at 72.8% and 68.9% in *C. freundii* isolates; and 42.9% and 42.9% in *C. braakii* isolates, respectively from the study of Zhang et al. [29], and 63.3% and 26.7% in *C. freundii* from the study of Yang *et al.* [31]. This difference could be due to different regions of China or the sources of samples.

3.6. Citrobacter spp. Carried Many Variants of the qnrB Gene with C. freundii Lineage I as the Main Reservoir

qnrB is known to be harbored by *Citrobacter* [26]. Surprisingly our *Citrobacter* isolates harboured many *qnrB* variants with 11 *qnrB* allelic variants found, including *qnrB2*, *qnrB9*, *qnrB13*, *qnrB16*, *qnrB17*, *qnrB63*, *qnrB76*, *qnrB77*, *qnrB92*, *qnrB93* and *qnrB94*. Interestingly, although only 17% (28 of 161) of the *C. freundii* isolates harbored *qnrB* genes, all except one *qnrB* positive isolate belonged to Lineage I, suggesting that Lineage I is a main reservoir of *qnrB* genes. However, carriage of *qnrB* gene does not always confer high level of quinolone resistance [29]. Only two *qnrB9*-carrying *C. freundii* isolates in Lineage I were susceptible to NAL, CIP and LEV. The only *qnrB* carrying Lineage II isolate is quinolones resistant. Four *qnrB*-carrying *C. braakii* isolates were resistant to NAL (MICs \geq 128 µg/mL). These results suggest that *Citrobacter* isolates carrying different *qnrB* alleles may have different levels of quinolone resistance.

QnrB has a growing number of allelic variants [32]. In our previous study, we found a variant of *qnrB77* (a *qnrB77* contained a LexA binding site) and a new *qnrB* allele (*qnrB92*) [10,16]. In this study, we found a variant of *qnrB76* (a *qnrB76* contained a LexA binding site), a variant of *qnrB13* (a *qnrB13* contained a LexA binding site), and two new *qnrB* alleles, *qnrB93* and *qnrB94*.

4. Conclusions

We analyzed 128 *Citrobacter* isolates (67 *C. freundii*, 16 *C. youngae* and 45 *C. braakii* isolates) from human diarrheal patients, foods and environment in Shijiazhuang, Hebei Province in the north of China. This study expands the genetic diversity observed from our previous studies of human and food isolates from South China [10,16]. The isolates showed high diversity with 123 STs of which 101 were novel STs. Only 22 STs (17.9%) were found from different sources and/or geographic regions. Phylogenetic analysis divided the 128 isolates into five lineages. Lineages I and II contained *C. freundii* isolates, while Lineages IV and V contained *C. youngae* isolates and Lineage III contained all *C. braakii* isolates.

The 51 MDR isolates were mainly distributed in Lineage I (*C. freundii*) and Lineage III (*C. braakii*) with 48.3% and 46.7% of the isolates in these lineages being MDR, respectively. Food isolates were also more likely to be MDR. Combining data with our previous studies [10,16], we found that the prevalence of quinolone resistance was highest in Lineage I (*C. freundii*) and Lineage III (*C. braakii*). *Citrobacter spp.* carried many variants of the *qnrB* gene with the carriage by *C. freundii* Lineage I isolates being the highest. Surprisingly, the prevalence of ESBL genes in *Citrobacter spp.* is relatively low.

There were 22 highly cytotoxic *Citrobacter* isolates, which were preferentially distributed in *C. freundii* Lineage II and *C. youngae* Lineage V, suggesting that these two lineages are more virulent than others, and thus, more likely to cause disease. This study has shed more light on the genetic diversity, pathogenicity and antibiotic resistance of *Citrobacter*.

5. Methods

5.1. Citrobacter Isolates

128 *Citrobacter* spp. isolates were isolated from 50 diarrheal patients, 11 environment and 67 food samples in Shijiazhuang Hebei Province, China from 2016 to 2017. 50 diarrheal patient fecal samples included 30 *C. freundii*, eight *C. braakii* and 12 *C. youngae* isolates, and four of the 50 diarrheal patient fecal samples harbored *norovirus* (HB2016002 and HB2017022) or *Vibrio parahaernolyticus* (HB2016004 and HB2016036); the 11 environment isolates had seven *C. freundii* and four *C. braakii* which were isolated from food processing place; 67 food isolates included 30 *C. freundii*, 33 *C. braakii* and four *C. youngae* isolates which were isolated from chicken, pork, duck and vegetables (Supplementary Table S4). The species identity of each isolate was confirmed using API 20E test strips (bioMérieux, La Balme les Grottes, France). Bacterial culture media and conditions were as previously described [10].

5.2. MLST and Phylogenetic Analysis

The *Citrobacter* MLST scheme (http://pubmlst.org/*cfreundii*/) was used. PCR amplification and sequencing were carried out using published primers as described previously [10]. SeqMan 7.0 software was used to analyze the sequences.

5.3. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing was carried out as previously described [10,33]. Minimum inhibitory concentration (MIC) was interpreted in 22 antibiotics, including ampicillin, cefotaxime, ceftazidime, cefepime, cefoxitin, ceftiofur Sodium, aztreonam, imipenem, meropenem, nalidixicacid, ciprofloxacin, levofloxacin, gentamicin, amikacin, streptomycin, kanamycin, tetracycline, doxycycline, chloramphenicol, trimethoprim/sulfamethoxazole, sulfafurazole and azithromycin (Table 2). *E. coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as quality controls for MICs.

5.4. PCR Amplification and Sequencing.

Detection of *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M-1}, *bla*_{CTX-M-2}, *bla*_{CTX-M-8}, *bla*_{CTX-M-9}, *bla*_{GES}, *bla*_{PER} and *bla*_{VEB}, *qnrA*, *qnrB*, *qnrC*, *qnrD*, *aac*(6')-*lb*-*cr* and *qepA* genes were carried out as previously described [10,34–39].

5.5. In Vitro Adhesion and Cytotoxicity Assays.

The human epidermoid laryngocarcinoma (HEp-2, CCC0068) cell line was obtained from the cell resource center at Peking Union Medical College. HEp-2 cell line has been used as a human cell line to study bacteria-host interactions in many studies [40–42]. Note that Hep-2 cell line may have been a misidentified cell line, raising concerns of relevance to laryngeal cancer research [43], but the issue is not relevant here. *In vitro* adhesion to host cells was performed as previously described [10]. The mean number of bacteria per HEp-2 after examination of 10 visual fields was determined and was used as an adhesion index (<1; >1 and <50; >50) [10].

The lactate dehydrogenase (LDH) released by the HEp-2 cells was determined as previously described [10]. All experiments were performed three times in duplicate.

5.6. Statistical Analysis.

SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA) was used to conduct all statistical comparisons. A nonparametric test (Mann–Whitney U-test) and chi-square test were used to compare the different groups for statistical significance. *p*-value of ≤ 0.05 (2-tailed) was considered to be statistically significant.

5.7. Ethics Approval and Consent to Participate

This study was reviewed and approved by the ethics committee of the National Institute for Communicable Disease Control and Prevention, the Chinese CDC. Human fecal specimens were acquired with the written informed consent of the diarrheal patients with the approval of the ethics committee of the National Institute for Communicable Disease Control and Prevention, according to the medical research regulations of Ministry of Health (ICDC-2016004).

Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/3/195/s1, Figure S1, Phylogenetic relationships as determined by MLST data for the 123 *C. freundii* isolates from this study and two previous studies; Table S1, List of clonal complexes of *Citrobacter* isolates from this study and the public MLST database[#]; Table S2, Prevalence of MDR isolates in different *Citrobacter* species; Table S3, Adherence and Cytotoxicity in 128 *Citrobacter* Isolates; Table S4, Source, drugs resistance, Genotypes and Antibiotic resistance phenotype of 128 *Citrobacter* Isolates.

Author Contributions: Formal Analysis, L.Q., S.H., X.L., X.C., C.Z. and H.S.; Resources, B.X., Y.G. and R.J.; Writing–Original Draft Preparation, L.L.; Writing–review and editing, L.L. and R.L.; Supervision, J.X. All authors have read and approved the final version of the manuscript.

Funding: This research was funded by the National Natural Science Foundation of China (No. 81301401, 81290345), and the National Key Research and Development Program of China (2016YFC1201903, 2016YFC1202700).

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Park, Y.-J.; Yu, J.K.; Lee, S.; Oh, E.J.; Woo, G.-J. Prevalence and diversity of qnr alleles in AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Serratia marcescens: A multicentre study from Korea. *J. Antimicrob. Chemother.* **2007**, *60*, 868–871. [CrossRef] [PubMed]
- 2. Guerrant, R.L.; Dickens, M.D.; Wenzel, R.P.; Kapikian, A.Z. Toxigenic bacterial diarrhea: Nursery outbreak involving multiple bacterial strains. *J. Pediatr.* **1976**, *89*, 885–891. [CrossRef]
- 3. Tschäpe, H.; Prager, R.; Streckel, W.; Fruth, A.; Tietze, E.; Böhme, G. Verotoxinogenic Citrobacter freundii associated with severe gastroenteritis and cases of haemolytic uraemic syndrome in a nursery school: Green butter as the infection source. *Epidemiol. Infect.* **1995**, *114*, 441–450. [CrossRef] [PubMed]
- 4. Warner, R.D. A large nontypical outbreak of Norwalk virus. Gastroenteritis associated with exposing celery to nonpotable water and with Citrobacter freundii. *Arch. Intern. Med.* **1991**, *151*, 2419–2424. [CrossRef] [PubMed]
- 5. Doulgeraki, A.; Paramithiotis, S.; Nychas, G.-J.E. Characterization of the Enterobacteriaceae community that developed during storage of minced beef under aerobic or modified atmosphere packaging conditions. *Int. J. Food Microbiol.* **2011**, *145*, 77–83. [CrossRef]
- 6. Giammanco, G.M.; Aleo, A.; Guida, I.; Mammina, C. Molecular Epidemiological Survey of Citrobacter freundii Misidentified as Cronobacter spp. (Enterobacter sakazakii) and Enterobacter hormaechei Isolated from Powdered Infant Milk Formula. *Foodborne Pathog. Dis.* **2011**, *8*, 517–525. [CrossRef]
- Samonis, G.; Karageorgopoulos, D.; Kofteridis, D.P.; Matthaiou, D.; Sidiropoulou, V.; Maraki, S.; Falagas, M.E. Citrobacter infections in a general hospital: Characteristics and outcomes. *Eur. J. Clin. Microbiol. Infect. Dis.* 2008, 28, 61–68. [CrossRef]
- 8. Mohanty, S.; Singhal, R.; Sood, S.; Dhawan, B.; Kapil, A.; Das, B.K. Citrobacter infections in a tertiary care hospital in Northern India. *J. Infect.* **2007**, *54*, 58–64. [CrossRef]
- 9. Bai, L.; Xia, S.; Lan, R.; Liu, L.; Ye, C.; Wang, Y.; Jin, N.; Cui, Z.; Jing, H.; Xiong, Y.; et al. Isolation and Characterization of Cytotoxic, Aggregative Citrobacter freundii. *PLoS ONE* **2012**, *7*, e33054. [CrossRef]
- 10. Liu, L.; Lan, R.; Liu, L.; Wang, Y.; Zhang, Y.; Wang, Y.; Xu, J. Antimicrobial Resistance and Cytotoxicity of Citrobacter spp. in Maanshan Anhui Province, China. *Front. Microbiol.* **2017**, *8*, 1357. [CrossRef]
- 11. Chen, K.J.; Chen, T.H.; Sue, Y.M. Citrobacter Youngae and Pantoea Agglomerans Peritonitis in a Peritoneal Dialysis Patient. *Perit. Dial. Int.* **2013**, *33*, 336–337. [CrossRef] [PubMed]
- Basra, P.; Koziol, A.; Wong, A.; Carrillo, C. Complete Genome Sequences of Citrobacter braakii Strains GTA-CB01 and GTA-CB04, Isolated from Ground Beef. *Genome Announc.* 2015, *3*, e01307-14. [CrossRef] [PubMed]

- Kwak, H.L.; Han, S.K.; Park, S.; Park, S.H.; Shim, J.Y.; Oh, M.; Ricke, S.; Kim, H.Y. Development of a rapid and accurate identification method for Citrobacter species isolated from pork products using a Matrix-Assisted Laser-Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOFMS). *J. Microbiol. Biotechnol.* 2015, 25, 1537–1541. [CrossRef] [PubMed]
- 14. Arens, S.; Verhaegen, J.; Verbist, L. Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. *Clin. Microbiol. Infect.* **1997**, *3*, 53–57. [CrossRef]
- 15. Chao, C.-T.; Lee, S.-Y.; Yang, W.-S.; Chen, H.-W.; Fang, C.-C.; Yen, C.-J.; Chiang, C.-K.; Hung, K.-Y.; Huang, J.-W. Citrobacter Peritoneal Dialysis Peritonitis: Rare Occurrence with Poor Outcomes. *Int. J. Med Sci.* **2013**, *10*, 1092–1098. [CrossRef]
- Liu, L.; Chen, D.; Liu, L.; Lan, R.; Hao, S.; Jin, W.; Sun, H.; Wang, Y.; Liang, Y.; Xu, J. Genetic Diversity, Multidrug Resistance, and Virulence of Citrobacter freundii From Diarrheal Patients and Healthy Individuals. *Front. Microbiol.* 2018, *8*, 233. [CrossRef]
- 17. Akya, A.; Jafari, S.; Ahmadi, K.; Elahi, A. Frequency Of blaCTX-M, blaTEM and blaSHV Genes in Citrobacters Isolated from Imam Reza Hospital in Kermanshah. *J. Mazand. Univ. Med. Sci.* **2015**, *25*, 65–73.
- 18. Oliveira, H.; Pinto, G.; Oliveira, A.; Oliveira, C.; Faustino, M.A.; Briers, Y.; Domingues, L.; Azeredo, J. Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates. *Appl. Microbiol. Biotechnol.* **2016**, *100*, 10543–10553. [CrossRef]
- Moland, E.S.; Hanson, N.D.; Black, J.A.; Hossain, A.; Song, W.; Thomson, K.S. Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002. *J. Clin. Microbiol.* 2006, 44, 3318–3324. [CrossRef]
- Choi, S.-H.; Lee, J.E.; Park, S.J.; Kim, M.-N.; Choo, E.J.; Kwak, Y.G.; Jeong, J.-Y.; Woo, J.H.; Kim, N.J.; Kim, Y.S. Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. *Eur. J. Clin. Microbiol. Infect. Dis.* 2007, 26, 557–561. [CrossRef]
- Shao, Y.; Xiong, Z.; Li, X.; Hu, L.; Shen, J.; Li, T.; Hu, F.; Chen, S. Prevalence of plasmid-mediated quinolone resistance determinants in Citrobacter freundii isolates from Anhui province, PR China. *J. Med Microbiol.* 2011, 60, 1801–1805. [CrossRef] [PubMed]
- 22. Minarini, L.; Darini, A.L.C. Mutations in the quinolone resistance-determining regions of gyrA and parC in Enterobacteriaceae isolates from Brazil. *Braz. J. Microbiol.* **2012**, *43*, 1309–1314. [CrossRef] [PubMed]
- 23. Weigel, L.M.; Steward, C.D.; Tenover, F.C. gyrA Mutations Associated with Fluoroquinolone Resistance in Eight Species of Enterobacteriaceae. *Antimicrob. Agents Chemother.* **1998**, *42*, 2661–2667. [CrossRef] [PubMed]
- 24. Feil, E.J. Small change: Keeping pace with microevolution. *Nat. Rev. Genet.* **2004**, *2*, 483–495. [CrossRef] [PubMed]
- 25. Wirth, T.; Falush, D.; Lan, R.; Colles, F.; Mensa, P.; Wieler, L.H.; Karch, H.; Reeves, P.; Maiden, M.C.; Ochman, H.; et al. Sex and virulence in Escherichia coli: An evolutionary perspective. *Mol. Microbiol.* **2006**, *60*, 1136–1151. [CrossRef]
- 26. Jacoby, G.; Cattoir, V.; Hooper, D.; Martínez-Martínez, L.; Nordmann, P.; Pascual, A.; Poirel, L.; Wang, M. qnr Gene Nomenclature. *Antimicrob. Agents Chemother.* **2008**, *52*, 2297–2299. [CrossRef]
- 27. Liu, X.; Huang, Y.; Xu, X.; Zhao, Y.; Sun, Q.; Zhang, Z.; Zhang, X.; Wu, Y.; Wang, J.; Zhou, N.; et al. Complete Genome Sequence of Multidrug-Resistant Citrobacter freundii Strain P10159, Isolated from Urine Samples from a Patient with Esophageal Carcinoma. *Genome Announc.* **2016**, *4*, e01754-15. [CrossRef]
- Harada, K.; Shimizu, T.; Ozaki, H.; Kimura, Y.; Miyamoto, T.; Tsuyuki, Y. Characterization of Antimicrobial Resistance in Serratia spp. and Citrobacter spp. Isolates from Companion Animals in Japan: Nosocomial Dissemination of Extended-Spectrum Cephalosporin-Resistant Citrobacter freundii. *Microorganisms* 2019, 7, 64. [CrossRef]
- Liu, L.-H.; Wang, N.-Y.; Wu, A.Y.-J.; Lin, C.-C.; Lee, C.-M.; Liu, C.-P. Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. *J. Microbiol. Immunol. Infect.* 2018, *51*, 565–572. [CrossRef]
- 30. Zhang, R.; Ichijo, T.; Huang, Y.-L.; Cai, J.; Zhou, H.; Yamaguchi, N.; Nasu, M.; Chen, G.-X. High prevalence of qnr and aac(6')-Ib-cr genes in both water-borne environmental bacteria and clinical isolates of Citrobacter freundii in China. *Microbes Environ.* **2012**, *27*, 158–163. [CrossRef]

- Yang, H.; Chen, H.; Yang, Q.; Chen, M.; Wang, H. High Prevalence of Plasmid-Mediated Quinolone Resistance Genes qnr and aac(6')-Ib-cr in Clinical Isolates of Enterobacteriaceae from Nine Teaching Hospitals in China. *Antimicrob. Agents Chemother.* 2008, 52, 4268–4273. [CrossRef] [PubMed]
- 32. Jacoby, G.A.; Griffin, C.M.; Hooper, D.C. Citrobacter spp. as a Source of qnrB Alleles. *Antimicrob. Agents Chemother.* **2011**, *55*, 4979–4984. [CrossRef] [PubMed]
- Clinical and Laboratory Standards Institute. M100-S28 Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Eighth Informational Supplement; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018; p. 353.
- Poirel, L.; Walsh, T.; Cuvillier, V.; Nordmann, P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn. Microbiol. Infect. Dis.* 2011, 70, 119–123. [CrossRef] [PubMed]
- 35. Voets, G.M.; Fluit, A.C.; Scharringa, J.; Stuart, J.C.; Hall, M.A.L.-V. A set of multiplex PCRs for genotypic detection of extended-spectrum β-lactamases, carbapenemases, plasmid-mediated AmpC β-lactamases and OXA β-lactamases. *Int. J. Antimicrob. Agents* **2011**, *37*, 356–359. [CrossRef] [PubMed]
- 36. Liu, Y.-Y.; Wang, Y.; Walsh, T.; Yi, L.-X.; Zhang, R.; Spencer, J.; Doi, Y.; Tian, G.; Dong, B.; Huang, X.; et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. *Lancet Infect. Dis.* 2016, 16, 161–168. [CrossRef]
- 37. Xavier, B.B.; Lammens, C.; Ruhal, R.; Kumar-Singh, S.; Butaye, P.; Goossens, H.; Malhotra-Kumar, S. Identification of a novel plasmid-mediated colistin-resistance gene,mcr-2, inEscherichia coli, Belgium, June 2016. *Eurosurveillance* **2016**, *21*, 30280. [CrossRef]
- 38. Zhao, W.-H.; Hu, Z.-Q. IMP-type metallo-?-lactamases in Gram-negative bacilli: Distribution, phylogeny, and association with integrons. *Crit. Rev. Microbiol.* **2011**, *37*, 214–226. [CrossRef]
- Frank, J.A.; Reich, C.I.; Sharma, S.; Weisbaum, J.S.; Wilson, B.A.; Olsen, G.J. Critical Evaluation of Two Primers Commonly Used for Amplification of Bacterial 16S rRNA Genes. *Appl. Environ. Microbiol.* 2008, 74, 2461–2470. [CrossRef]
- 40. Mange, J.-P.; Stephan, R.; Borel, N.; Wild, P.; Kim, K.S.; Pospischil, A.; Lehner, A. Adhesive properties of Enterobacter sakazakii to human epithelial and brain microvascular endothelial cells. *BMC Microbiol.* **2006**, *6*, 58. [CrossRef]
- Dallal, M.M.S.; Validi, M.; Douraghi, M.; Fallah-Mehrabadi, J.; Lormohammadi, L. Evaluation the cytotoxic effect of cytotoxin-producing Klebsiella oxytoca isolates on the HEp-2 cell line by MTT assay. *Microb. Pathog.* 2017, *113*, 416–420. [CrossRef]
- Konkel, M.E.; Joens, L.A. Adhesion to and invasion of HEp-2 cells by Campylobacter spp. *Infect. Immun.* 1989, 57, 2984–2990. [CrossRef] [PubMed]
- 43. Philippe, G. A comprehensive review of Hep-2 cell line in translational research for laryngeal cancer. *Am. J. Cancer Res.* **2019**, *9*, 644–649.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).